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Subfertility, defined as at least one year of unprotected intercourse with the same partner 
without conception, affects ten to fifteen percent of couples in the western world. Depend-
ing on the duration of the subfertility, a female factor is the dominant cause of subfertility 
in around 50%, a male factor in 20-26% and the cause is unexplained in 25-30% (1). In 
most couples, subfertility is of multifactorial origin and should therefore be considered 
as a complex disease (2). Whereas genetic causes are difficult to modulate, environmental 
and lifestyle factors implicated in reproduction are potentially amendable to curative or 
preventive measures. Worldwide, an increasing number of couples are treated by assisted 
reproductive technology (ART) to achieve pregnancy (3, 4). Currently, the chance of achiev-
ing a clinical pregnancy is around 28-31% per started in vitro fertilization (IVF) cycle with 
or without intracytoplasmic sperm injection (ICSI) in the Netherlands (5). The advantage of 
the introduction of IVF and ICSI treatment is that it gives access to and information about 
the direct environment of the gametes and early developing embryo. On the other hand, 
IVF and ICSI treatment is introducing an artifactual endocrinologic milieu which may affect 
the quality of the embryo. Whether concentrations of nutrients and enzymes change due 
to ovarian hyperstimulation is unclear, but it has already been demonstrated that different 
ovarian stimulation regimens increase the rates of embryo aneuploidy (6).
Follicular fluid represents the direct environment of maturing oocytes. Likewise, 
spermatozoa in the ejaculate are surrounded by seminal plasma, which contains a broad 
spectrum of components, including nutrients and enzymes, which protect the sperm and 
maintain its motility. Conventional determinants of sperm quality consist of the semen 
parameters volume, sperm concentration, motility and morphology. The DNA fragmen-
tation index (DFI) as assessed by the Sperm Chromatin Structure Assay (SCSA), is also 
considered as an independent measure of sperm quality, with even a better diagnostic 
and prognostic capability than the conventional semen parameters (7, 8).
Evidence for an important role of the homocysteine pathway in fertility is increasing 
(9, 10). In this pathway the B-vitamins folate, cobalamin and pyridoxine serve as cofactors 
(Figure 1). Several intermediates of the homocysteine pathway are directly involved in the 
synthesis of proteins, the synthesis and repair of DNA, and balance the degree of oxidative 
stress, which are critical intermediates in gametogenesis. Therefore, derangements in this 
pathway in both women and men resulting in hyperhomocysteinaemia, are suggested 
to be detrimental for reproduction (9). Maternal hyperhomocysteinaemia is associated 
with adverse pregnancy outcome, such as recurrent miscarriages, pregnancy induced 
hypertension, abruptio placentae and several congenital abnormalities (11-16). The 
importance of the maternal folate status in the development of neural tube defects (NTD) 
and other congenital abnormalities, such as orofacial clefts and congenital heart disease 
is well known (17-19). In addition, a population-based, matched, case-control study dem-
onstrated an association between low maternal plasma folate and an increased risk of 
early spontaneous abortion (20). Similarly, maternal low cobalamin (vitamin B12) status 
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has been associated with a higher risk of neural tube defects and spontaneous abortions 
(10, 21-23). Recent case-control studies showed a reduction in the risk of orofacial clefts 
(24) and some decrease in congenital heart disease by pyridoxine (vitamin B6) (25). Pyri-
doxine may also have a role in the prevention of pre-eclampsia (26) and preterm birth (27). 
However, in a recent Cochrane review it was concluded that there is not enough evidence 
to detect clinical benefits of pyridoxine supplementation in pregnancy (28).
Recent publications suggest that the homocysteine pathway is not only important 
for reproductive outcome, but for fertility as well (10, 29, 30). This subject is rather new 
and requires further investigation. After an overview of the literature on the role of the 
homocysteine pathway in human subfertility, the objectives and outline of this thesis are 
described.
The homoCysTeine PaThway in human suBFerTiLiTy
Homocysteine
In the homocysteine metabolism 5-methyltetrafolate (5-methyl-THF), the reduced form 
of folate, is the primary methyl donor for remethylation of total homocysteine (tHcy) into 
methionine (Figure 1). Methionine synthase, using cobalamin as co-factor, is essential 
 
Figure 1. The homocysteine pathway
5-methyl-THF = 5-methyltetrafolate; MS = methionine synthase; B12 = cobalamin; B6 = pyridoxal 
’5-phosphate; dTMP = deoxythymidine ‘5-monophosphate; dUMP = deoxyuridine ‘5-monophosphate; 
TS = thymidylate synthase; DHF = dihydrofolate; THF = tetrahydrofolate; MTHFR = 5,10-methylene-
THF reductase; DMG = dimethylglycine; BHMT = betaine homocysteine methyltransferase; SAM = 
S-adenosylmethionine; SAH = S-adenosylhomocysteine; CBS = cystathione synthase.
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in this conversion. Methionine provides the methyl groups necessary for the formation 
of S-adenosylmethionine, which is involved in numerous cellular reactions, including 
methylation of phospholipids, proteins, DNA, RNA, amino acids and neurotransmitters. 
Hyperhomocysteinaemia can be induced by genetic factors, for example cystathione 
synthase (CBS) deficiencies or the MTHFR 677 C→T polymorphism, but also by a deficient 
intake of folate, cobalamin or pyridoxine (31). Around 50% of tHcy is transformed into 
cysteine for which pyridoxine is required as a cofactor.
The reported detrimental effects of high tHcy are direct cellular toxicity, endothelial 
damage, excessive generation of reactive oxygen species (ROS), inhibition of transmethy-
lation reactions, and aberrant gene expressions. Physiological levels of ROS in follicular 
fluid are necessary for oocyte maturation (32), ovulation (33) and fertilization (9). However, 
high tHcy in follicular fluid may also increase the release of ROS, thereby inducing exces-
sive oxidative stress.
A significant correlation between the concentration of tHcy in blood and follicular 
fluid has been established (34). A Polish group demonstrated significantly lower tHcy 
concentrations in follicular fluid and blood in folic acid supplemented women (35). Total 
homocysteine has also been determined in seminal plasma (29). Recently, an association 
has been demonstrated between high tHcy concentrations both in follicular fluid and the 
ejaculate and a higher risk of moderate to low embryo quality in IVF treatment (29).
Folate
Folate is a B-vitamin present in its natural form in fruits and vegetables. Folic acid is the 
synthetic form of folate and used in supplements and fortified foods, because of its high 
bioavailability and chemical stability. Folate is required for the synthesis of thymine and 
purines, precursors for DNA and RNA synthesis, and for DNA methylation and repair. A 
deficient intake of folate induces a mild hyperhomocysteinaemia. Since the early nineties 
periconception folic acid use is recommended to women planning pregnancy in order to 
prevent NTDs (36, 37). Whether the use of folic acid leads to an increased rate of twinning 
is still a subject of debate (38-41).
A significant correlation between the concentration of folate in blood and follicular fluid 
has been established (34). Similarly, folate concentrations in seminal plasma and blood are 
significantly correlated (42). Moreover, in seminal plasma other folate metabolites than 
methyl-tetrahydrofolate positively correlated with sperm density and total sperm count 
(42). Further evidence for the significant role of folate in spermatogenesis is derived from 
a randomized controlled trial demonstrating a 74% increase in sperm count in subfertile 
men after folic acid and zinc sulphate intervention for six months (30). Independent of 
the fertility state, sperm concentration significantly increased in wild types C677T MTHFR 
polymorphism, suggesting a role of folate genes in spermatogenesis (43).
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Cobalamin
Cobalamin, or vitamin B12, is a B-vitamin present in animal products, such as beef, fish, 
eggs and milk. Several small studies and case reports in the sixties and seventies described 
cobalamin deficient subfertile women who became pregnant after cobalamin suppletion, 
but the underlying mechanisms are not clear (21, 44-47). Cobalamin concentrations in 
blood and follicular fluid are significantly correlated (34).
Likewise the effect of cobalamin on sperm quality is not clarified, although there is 
some evidence that this B-vitamin affects sperm parameters (48, 49). During the sixties 
and seventies several studies described the successful treatment of subfertile men follow-
ing treatment of a cobalamin deficiency (50, 51).
Pyridoxine
Pyridoxine, or vitamin B6, is present in a variety of foods with a high content in soybeans, 
bran rice, walnuts and chicken breast. Vitamin B6-dependent coenzymes participate in 
numerous reactions involved in the metabolism of amino acids, heme, and myelin syn-
thesis (28). Vitamin B6 deficiency has also been associated with impairment of enzymes 
involved in the structural integrity of arterial walls (52), which could affect implantation 
and early placental development.
In a prospective observational study in Chinese women, deficient pyridoxine concen-
trations in blood were associated with lower conception rates and a higher rate of early 
pregnancy loss (53). Pyridoxine has previously been determined in follicular fluid (34).
There is no information about the effects of pyridoxine on male reproduction. Pyridox-
ine has not been determined in human seminal plasma before. From animal studies it is 
known that high doses of pyridoxine impair sperm motility and sperm count and cause 
histopathological changes including degeneration of germinal epithelial cells (54, 55).
In conclusion, derangements of the homocysteine pathway are associated with param-
eters that may affect fertility. For the interpretation of the associations between biomarker 
concentrations and fertility outcome parameters it is important to know whether clinical 
factors, such as ovarian hyperstimulation, are affecting concentrations of the biomarkers 
of the homocysteine pathway. Moreover, most studies used multifollicular fluids instead of 
the more precise monofollicular fluids. Furthermore, biomarker concentrations have not 
been studied in association with sperm DNA-damage and the achievement of pregnancy. 
Therefore, the aim of this thesis is to further study the homocysteine pathway by improved 
methodologies en techniques in association with parameters of human fertility.
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oBJeCTiVes oF This Thesis
The main objective was to investigate the role of the homocysteine pathway in human 
fertility.
The detailed objectives of Part I (Women):
- To identify factors that affect folate and tHcy in follicular fluid.
- To investigate whether ovarian hyperstimulation changes B-vitamins and tHcy in 
blood.
- To determine associations between B-vitamins and tHcy in blood and follicular fluid 
and parameters of oocyte quality.
- To investigate associations between B-vitamins and tHcy in blood and follicular fluid 
and the outcome of IVF.
The detailed objectives of Part II (Men):
- To investigate associations between B-vitamins and tHcy in blood and seminal 
plasma.
- To investigate associations between B-vitamins and tHcy in blood and seminal plasma 
and conventional semen parameters and DFI.
ouTLine oF The Thesis
In Part I biomarkers of the homocysteine pathway are studied in women undergoing an 
IVF or ICSI treatment. Chapter 2 describes a pilot study in which factors affecting con-
centrations of biomarkers from the homocysteine pathway in follicular fluid are investi-
gated. In chapter 3 associations between these biomarkers in multifollicular fluid and IVF 
outcome are investigated in the same study. Subsequently, a prospective observational 
study is performed in which blood, monofollicular fluid and information about the IVF 
outcome is obtained from women undergoing IVF or ICSI treatment. The effects of ovarian 
hyperstimulation on tHcy and B-vitamins determined in blood are studied in chapter 4. In 
chapter 5 associations between these biomarkers in blood and monofollicular fluid and 
IVF outcome are investigated.
In Part II biomarkers of the homocysteine pathway are studied in men of couples under-
going an IVF or ICSI treatment. In chapter 6 and 7, associations between concentrations 
of tHcy, folate, cobalamin, and pyridoxine in blood and seminal plasma are determined. 
Chapter 6 describes associations between biomarker concentrations and semen param-
eters, including volume, sperm concentration, total sperm count, progressive motility and 
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normal morphology. In addition to the conventional semen analysis, the DFI is studied 
in chapter 7. In this chapter associations between the biomarkers of the homocysteine 
pathway in blood and seminal plasma and conventional semen parameters as well as DFI 
are studied.
Finally, chapter 8 provides a general discussion of the main findings and reflects on impli-
cations for clinical practice and future research.
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PART I
The homocysteine pathway, 
female fertility and IVF outcomes

Chapter 2
Preconception folic acid 
treatment affects the micro-
environment of the maturing 
oocyte in human
Jolanda C. Boxmeer, R. Montserrate Brouns, Jan Lindemans,  
Eric A.P. Steegers, Elena Martini, Nick S. Macklon, Régine P.M. 
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aBsTraCT
study objective: To investigate the influence of folic acid supplementation on the fol-
licular fluid concentrations of folate and total homocysteine and their relationship to the 
diameter of the follicle.
Design: Observational study.
setting: Tertiary referral fertility clinic at the Erasmus MC, University Medical Center, Rot-
terdam, The Netherlands.
Patients: Thirty-seven women undergoing IVF or ICSI treatment.
interventions: No interventions other than routine stimulation treatment and the recom-
mendation of folic acid supplementation.
main outcome measures: Concentrations of folate and total homocysteine in monofol-
licular and pooled follicular fluid, and the diameter of the follicle.
results: Folic acid supplementation significantly increased folate and decreased total 
homocysteine concentrations in pooled follicular fluid. In monofollicular fluid folate 
concentrations only were significantly increased in supplemented women. The total 
homocysteine concentration appeared to be significantly correlated with the diameter 
of the follicle (r = 0.27). Samples from single follicles were less prone to artifacts in the 
measurements of the folate and total homocysteine concentration.
Conclusions: Preconception folic acid supplementation significantly alters both folate 
and total homocysteine concentrations in follicular fluid. The correlation between the 
diameter of the follicle and total homocysteine concentration in follicular fluid warrants 
further investigation.
Folate and homocysteine in follicular fluid 25
inTroDuCTion
A primary deficiency of natural folate resulting in an increase of the total homocysteine 
(tHcy) concentration may be detrimental to the quality of the oocyte, subsequent fertiliza-
tion, implantation, embryogenesis and fetal outcome (1-3). The presence of folate and tHcy 
in ovarian follicular fluid has previously been demonstrated (4). Interestingly, a low fol-
licular fluid homocysteine concentration has been reported to be associated with a higher 
degree of maturation of the oocyte (5). More recently, a significant inverse association 
between the tHcy concentration in follicular fluid and embryo quality was demonstrated 
in women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) 
treatment (6). Considerable evidence supports the preventive effects of periconception 
synthetic folic acid supplementation against the birth prevalence rate of several complex 
congenital malformations (7). Other beneficial reproductive effects of periconception folic 
acid use has been suggested as well (8). Although it has been suggested that folic acid 
supplementation stimulates the twinning rate, this is not yet clear (9, 10).
The B-vitamin folate is an important substrate in the synthesis of pyrimidines and purines. 
Moreover, folate is an important supplier of methyl groups to remethylate homocysteine 
into methionine. The methionine derivative S-adenosylmethionine is the most important 
methyl donor in the body for the methylation of lipids, proteins and DNA. Therefore, the 
cellular folate status is important for protein and DNA synthesis as well as the regulation 
of DNA expression by methylation. This is substantiated by molecular biologic studies 
that indicate that both folate deprivation and folic acid supplementation affect multiple 
metabolic pathways by controlling the expression of genes through methylation (11, 12).
During the preconception period gametogenesis and folliculogenesis take place, 
in which the requirement for folate is enhanced (13). After fertilization the blastocyst is 
demethylated, that is followed by the selective methylation of genes (12). A well-known 
marker of folate deficiency is an increased mean cell volume of red blood cells, which is 
defined as megaloblastic anemia. The underlying mechanism of this feature, however, is 
so far unknown. Whether other rapidly dividing cells show similar morphological features 
is not clear.
To further improve the methodology of future investigations into the influence of the 
microenvironment of the oocyte on its quality and the chance of successful fertilization, it 
is important to study some methodological issues as well. Therefore, the aims of this study 
are to examine: [1] the effects of preconception folic acid supplementation on follicular 
fluid concentrations of folate and tHcy in women undergoing IVF or ICSI treatment, [2] the 
differences between folate and tHcy concentrations in monofollicular and pooled follicular 
fluid, and [3] the correlations between folate, tHcy, and the diameter of the follicle.
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Population
Thirty-seven women with a median age of 34.4 years (range 27.2 - 40.7 years) underwent 
an IVF or ICSI treatment at the Department of Obstetrics and Gynecology, Division of 
Reproductive Medicine, Erasmus MC, University Medical Center, and were included in the 
study. The women were asked on the day of ovum pick up to report whether or not they 
were using supplements containing folic acid. The study protocol was performed, and the 
remnant follicular fluid samples were collected according to the guidelines of the Medical 
Ethical and Institutional Board of the Erasmus MC, University Medical Center in Rotterdam, 
The Netherlands.
Sample Collection
Follicular fluid was collected from each woman during ovum pick up from the largest fol-
licle in the first ovary and the smallest follicle 10 mm diameter or more in the other ovary; 
the mean diameters (range) were 22 (15 - 28) and 16.1 (10 - 20) mm, respectively. The fluids 
collected from all other aspirated follicles were pooled per woman. After oocyte retrieval 
for the IVF or ICSI procedure, the follicular fluid samples were centrifuged for 10 minutes 
at 1,700 x g to separate red blood cells, leucocytes, and granulosa cells.
Laboratory Analysis
Follicular fluid folate concentrations were measured using electrochemiluminescence 
immunoassay (Elecsys 2010, Roche GmbH, Mannheim, Germany), and tHcy was deter-
mined using high-performance liquid chromatography with fluorescence detection (14, 
15). The lowest detection limit for folate was 1.36 nmol/L and for tHcy 4 µmol/L. To adjust 
folate and tHcy concentrations for dilution by the medium used to flush the aspiration 
needle, total protein was measured colorimetrically using biuret reagent (Hitachi 917, 
Roche GmbH).
Statistical Methods
Statistical analyses were performed by the paired and two sample Wilcoxon rank tests. P ≤ 
.05 was considered statistically significant. In the comparisons of the folate and tHcy con-
centrations between monofollicular and pooled follicular fluid women were only included 
when the concentrations could be determined in two monofollicular fluid samples. All 
data were analysed in a mixed-model analysis to determine the correlation between the 
folate and tHcy concentrations and the diameter of the follicles.
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resuLTs
The median concentrations of folate and tHcy in monofollicular and pooled follicular 
fluids stratified for preconception folic acid supplementation are presented in Table 1. The 
concentrations of folate and tHcy are given as protein ratios to adjust for dilution by the 
medium used to flush the aspiration needle. The median folate concentrations were higher 
and the median tHcy were lower in the follicular fluid samples of folic acid supplement 
users compared with nonsupplement users. The differences were all significant in the 
pooled follicular samples. In the monofollicular samples, the folate concentrations only 
were statistically significantly higher in supplement users compared with nonsupplement 
users.
Overall the median folate concentrations were significantly higher in the pooled sam-
ples compared to the monofollicular samples (median, 0.55 and 0.48 nmol/g, respectively; 
P≤ 0.001), whereas tHcy concentrations were comparable in both samples (median, 0.12 
µmol/g).
The mixed-model analysis revealed a significant positive correlation between the 
monofollicular tHcy concentration and the diameter of the follicle (r = 0.268; P≤ 0.001. 
Every increase of the tHcy concentration by 0.0025 µmol/g increased the follicle diameter 
by 1 mm (P≤ 0.001). An inverse correlation, albeit small and not significant, between the 
concentration of folate and the diameter of the follicle was established (r = -0.052; P = 
0.11). The total protein concentration was not significantly correlated with the follicular 
diameter (Figure 1).
Sometimes the pooled samples were contaminated with blood. Therefore, we investi-
gated whether blood contamination may cause an artifactual increase in the follicular fluid 
folate concentration. In the pooled follicular fluid samples of six women we determined 
the folate concentration in two clear and in two visibly blood-contaminated samples of 
which one sample was centrifuged within 1 hour and one after 24 hours. The median 
folate concentration within 1 hour was 0.37 nmol/g in the clear samples and 0.47 nmol/g 
Table 1. Median folate and tHcy concentrations determined in monofollicular and pooled follicular fluids 
in IVF patients supplemented and nonsupplemented with folic acid.
Folic acid 
supplemented
Folic acid
not supplemented
P
Monofollicular samplesa:
 Folate/ total protein (range), nmol/g 0.50 (0.18-0.61) (n=16) 0.32 (0.08-0.38) (n=5) ≤ 0.001
 tHcy/ total protein (range), μmol/g 0.12 (0.06-0.18) (n=18) 0.12 (0.09-0.22) (n=8) NS
Pooled follicular samples:
 Folate/ total protein (range), nmol/g 0.57 (0.16-1.03) (n=21) 0.18 (0.10-0.79) (n=8) ≤ 0.01
 tHcy/ total protein (range), μmol/g 0.12 (0.08-0.22) (n=21) 0.15 (0.11-0.36) (n=8) ≤ 0.05
a Two single follicular fluid samples per patient.
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in the blood-contaminated samples. After 24 hours, the median folate concentrations 
were, respectively, 0.39 and 0.48 nmol/g.
DisCussion
This study shows that folic acid supplementation significantly increases the folate 
concentration and decreases the tHcy concentrations, albeit not significantly in mono-
follicular fluid, in the microenvironment of the maturing oocyte. The effect of folic acid 
supplementation on the folate-dependent homocysteine metabolism in follicular fluid 
was comparable to that in blood (4, 16).
The finding of a significant positive correlation between the diameter of the follicle 
and the follicular fluid concentration of tHcy was unexpected. Follicle fluid is a mixture of 
serum exudate and locally produced substances that are related to the metabolic activity 
of ovarian cells (17). It is not clear what determines the concentration of tHcy and folate 
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Figure 1. Correlations between the total protein, the folate/protein, and tHcy/protein ratios in follicular 
fluid and follicular diameter. The follicular fluid total protein concentration (graph A) and folate/protein 
ratio (graph B) are not significantly correlated with the diameter of the follicle. Graph C shows that the 
diameter of the follicle and the tHcy/protein ratio are significantly correlated. Every increase of the tHcy 
concentration by 0.0025 μmol/g, 95% confidence interval 0.0012 - 0.0036, was associated with an increase 
of the follicle diameter by 1 mm; P < 0.001.
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in follicular fluid. The statistically significant positive correlation between diameter and 
follicular fluid tHcy concentration may indicate that there is an increased production or 
leakage of tHcy via the granulosa cells or the oocyte and/or an enhanced requirement 
for folate in larger follicles. This might be caused by the evolution of the cells and/or the 
reaction to the hCG administration during the IVF treatment. Another explanation may 
be that there is an alteration of the exchange between the follicle and the surrounding 
cell layers during the maturation of the follicle, which causes a decrease of folate and an 
accumulation of tHcy. These findings, however, are in line with our previous study and that 
of others (5, 6).
Serum folate concentrations are inversely correlated with de size of red blood cells. 
Whether the same mechanisms are responsible for the growth or extension of the follicles 
and red blood cells is unknown. It is possible that osmolarity plays a role. However, our 
data may suggest that tHcy is involved as well. Whether an enhanced oxidative stress due 
to the high concentrations of tHcy affects the diameter of cells involved should be further 
elucidated. The inverse association between the follicular diameter and follicular folate 
concentration was statistically not significant. This may, however, be due to the small 
number of samples.
The consequences of a high concentration of tHcy in follicular fluid are not clear. Homo-
cysteine is a thiol known to induce the release of reactive oxygen species (ROS). Although 
ROS is important for oocyte maturation and fertilisation, high levels of ROS in the culture 
medium of embryos have been shown to result in low cleavage rates, high embryonic 
fragmentation and low rates of blastocyst formation (18). This is consistent with the 
reported inverse correlation between the tHcy concentration in follicular fluid, seminal 
plasma and embryo quality (5, 6). The observation that the prolongation of the follicular 
phase during IVF treatment decreases the chance of achieving an ongoing pregnancy may 
be explained by the extended detrimental exposure to high follicular tHcy concentrations 
that decreases oocyte quality (19, 20). More studies on this field, however, are required to 
determine the role of folate and tHcy in follicular fluid as an indicator of oocyte quality. 
Such studies are now underway.
We have shown that blood contamination is a problem in the collection of pooled fol-
licular samples. The results also demonstrated that the difference in folate concentration 
in follicular fluid as a result of oocyte aspiration could not be prevented by centrifugation 
within 1 hour after collection.
However, the absence of statistically significant differences in those concentrations 
with and without centrifugation within one hour after collection may be due to the small 
number of samples. It was shown that blood contamination could be avoided in most 
cases by taking monofollicular samples from the first follicle aspirated during oocyte 
pickup. Therefore, we recommend that monofollicular fluid samples or clear follicular fluid 
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samples should be collected in the future investigation of these nutrients in follicular fluid 
in association with several outcome parameters.
We calculated protein ratios of the folate and tHcy concentrations with the aim to of 
adjusting for dilution by the medium used to flush the aspiration needle. Total protein, 
however, appeared a constant determinant in follicular fluid, independent of the diameter 
of the follicle.
In conclusion, this study demonstrates a significant effect of folic acid supplementa-
tion on the follicular fluid folate and tHcy concentrations that thereby influence the 
microenvironment of the maturing oocyte. Of interest also is the finding that the diameter 
of the follicle is inversely correlated with the follicular fluid tHcy concentration. This may 
suggest that there is a particular range of the follicle diameter that reflects an optimal 
microenvironment of the maturing oocyte. Finally, blood contamination of the follicular 
fluid overestimates the folate concentration in follicular fluid. Therefore, in future studies, 
the collection of follicular fluid samples from monofollicles in women with and without 
folic acid supplementation is recommended.
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aBsTraCT
Derangements in the B-vitamin dependent homocysteine pathway are implicated in 
the pathophysiology of reproductive failures, but the role in fertility has scarcely been 
studied. Therefore, we determined the concentrations of total homocysteine (tHcy), 
folate, cobalamin and pyridoxine in follicular fluid of 143 women undergoing IVF or ICSI 
treatment. Relationships were determined between these biomarkers in follicular fluid 
and the number of oocytes, percentage of fertilization and the occurrence of biochemical 
pregnancy. Significant correlations were demonstrated between tHcy, folate, cobalamin, 
and pyridoxine concentrations in follicular fluid. Not any correlation was established 
between the biomarkers and fertilization. An inverse correlation was determined between 
tHcy and the number of oocytes after adjustment for age and treatment (r = -0.16; P < 
0.05). Moreover, the higher the tHcy concentration per follicle, the lower the chance of 
biochemical pregnancy (odds ratio = 0.56, 95% CI 0.34 - 0.95). These data suggest that a 
high follicular fluid tHcy concentration is detrimental for the number of maturated oocytes 
and the chance of achieving a biochemical pregnancy.
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inTroDuCTion
Subfertility occurs in around 10% of the couples during reproductive life. In about 30% 
of these couples no cause can be found (1). Evidence is increasing that nutritional factors 
play a significant role in reproduction. Of interest is the homocysteine pathway in which 
several nutrients are involved. This pathway has widely been studied in association with 
birth defects, miscarriages and hypertension-complicated pregnancies but only scarcely 
with regard to fertility parameters (2, 3).
The homocysteine pathway is important for delivering methyl groups by the intermedi-
ate S-adenosylmethionine, which is essential for the methylation of DNA and therefore 
genome regulation. Folate is an essential substrate in the remethylation of homocysteine 
into methionine by methionine synthase and for the synthesis of DNA- and RNA-precur-
sors. Cobalamin (vitamin B12) serves as a cofactor for methionine synthase. Vitamin B6, 
or pyridoxine, acts as a cofactor for cystathionine-beta-synthase enabling the transsul-
phuration of homocysteine into cystathionine and cysteine. A deficiency of one of these 
vitamins causes mild hyperhomocysteinemia, which is associated with cardiovascular and 
cerebrovascular diseases (4). Associations between maternal hyperhomocysteinemia and 
congenital malformations, recurrent pregnancy loss and abruptio placentae have been 
previously demonstrated (5-7). Folic acid treatment significantly reduces elevated total 
homocysteine (tHcy) concentrations (4). This may partially explain the beneficial effect of 
periconception folic acid supplementation against several complex congenital malforma-
tions (8). Whether folic acid supplementation may also increase the occurrence of twins is 
still a matter of debate (9, 10).
In the early nineties the presence of tHcy, folate, cobalamin and pyridoxine in follicular 
fluid was demonstrated (11). Moreover, women who received folic acid supplementation 
showed a significantly lower tHcy concentration in follicular fluid (12). Ebisch et al. showed 
that a high tHcy concentration was inversely associated with embryo quality (13). From 
this background we hypothesized that a derangement in the homocysteine pathway is 
detrimental to the quality of the oocyte, fertilization, implantation and embryogenesis. 
Therefore we aimed to investigate the relationships between the tHcy, folate, cobalamin 
and pyridoxine concentrations in follicular fluid of women undergoing in-vitro fertilization 
(IVF) with or without intracytoplasmic sperm injection (ICSI) treatment and the number of 
oocytes, fertilization and the occurrence of biochemical pregnancy.
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Subjects
One hundred forty-three women, median age (range); 33.7 (23.3 – 43.2) years, undergo-
ing IVF with or without ICSI treatment at the Department of Obstetrics and Gynecology, 
Division of Reproductive Medicine of the Erasmus MC, University Medical Center were 
included. On the day of ovum pick up the use of folic acid containing supplements was 
reported.
Follicular fluid
From each subject follicular fluid from all aspirated follicles was collected and pooled 
for analysis. Specimens were collected in accordance with the guidelines of the Medical 
Ethical and Institutional board of the Erasmus MC, University Medical Center in Rotterdam, 
The Netherlands. After oocyte retrieval for the IVF or ICSI procedure, the samples were 
centrifuged for 10 minutes at 1,700 g to separate red blood cells, leucocytes and granulosa 
cells from the follicular fluid.
The follicular fluid samples were analyzed for folate and cobalamin during routine 
laboratory procedures using an immunoelectrochemoluminescence assay (Roche 
Modular E170, Roche Diagnostics GmbH, Mannheim, Germany). Pyridoxine and tHcy were 
determined during routine laboratory procedures using high performance liquid chroma-
tography with reversed phase separation and fluorescence detection (14, 15). Pyridoxine 
was determined as pyridoxal’5-phosphate (PLP).
In order to adjust the concentrations for dilution by the medium used to flush the IVF 
aspiration needle, the total protein concentration was measured colorimetrically using 
biuret reagent (Hitachi 917, Roche GmbH, Mannheim, Germany). The detection limit for 
tHcy was 4 µmol/L, folate 1.36 nmol/L, cobalamin 22 pmol/L and PLP 5 nmol/L.
Fertility outcome parameters
The proportion of fertilized oocytes was calculated by dividing the number of oocytes 
with two pronuclei the day after oocyte retrieval by the total number of oocytes retrieved. 
Biochemical pregnancy was defined as a positive urinary hCG pregnancy test performed 
on day 15 after ovum pick up.
Statistical analysis
The results are expressed in median (range), number and percentage and analyzed for sta-
tistical significance using nonparametric tests, because of the skewed distributions of the 
B-vitamins and tHcy. Spearman rank correlation coefficients were calculated to determine 
associations between tHcy, folate, cobalamin and PLP concentrations in follicular fluid.
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To adjust for possible confounding variables, multivariable linear regression analysis 
was performed with the number of oocytes and the percentage of fertilized oocytes as 
dependent outcome variable. Logistic regression was performed for the occurrence of 
pregnancy as dependent outcome variable. Because age, the type of treatment (IVF or 
ICSI) and the presence of female factor subfertility are strong determinants of fertility 
outcome, these factors were considered as potential confounders. A P-value of < 0.05 was 
considered statistically significant. Statistical analyses were performed using SPSS 11.5 for 
Windows software (SPSS Inc, Chicago, Il, USA)
resuLTs
In Table 1 the characteristics of the study population and the B-vitamin and tHcy concen-
trations in follicular fluid are presented. Due to a limited sample volume the follicular fluid 
concentrations of tHcy, folate, cobalamin and PLP could not be determined in 1, 25, 3 and 
16 samples, respectively. The unadjusted median concentrations were for tHcy 6.6 μmol/L 
(range 3.1-33.4), folate 21.9 nmol/L (range 4.4 – 43.6), cobalamin 187.1 pmol/L (range 59.9-
561.4) and PLP 46 nmol/L (range 13-334).
In Table 2 the correlations between tHcy and the B-vitamins are shown. Table 3 depicts 
the correlations between the concentrations of tHcy and B-vitamins and the outcome of 
the IVF-treatment. A weak, but statistically significant inverse correlation between fol-
licular fluid tHcy and the number of retrieved oocytes could be established (r = –0.16; P < 
0.05) (Figure 1). Multivariable regression analysis revealed age and the type of treatment 
as significant confounders for the association between tHcy, B-vitamins and the number 
Table 1. Characteristics of the 143 women undergoing IVF/ICSI
Age (years) median (range) 33.7 (23.3-43.2)
Folic acid supplement use % (n) 63 (78)
Oocytes per patient, median (range) 8 (0-30)
ICSI % (n) 30 (43)
Proportion fertilized oocytes % (range) 59.8 (0-100)
Embryo transfer rate % (n) 85.3 (122)
Biochemical pregnancy rate % (n) 40.6 (58)
Follicular fluid concentrations, median (range)*: Per gram of protein
tHcy (μmol/g) 0.13 (0.07-0.70)
Folate (nmol/g) 0.41 (0.09-1.03)
Cobalamin (pmol/g) 3.88 (1.22-16.04)
Pyridoxine (nmol/g) 0.89 (0.28-9.21)
* Concentrations are determined in the individually pooled follicle fluid. The ratio of these concentrations 
per gram of total protein is calculated to adjust for dilution by the flushing medium.
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of oocytes. Female factor subfertility was a significant confounder for the correlations 
between tHcy, B-vitamins and the percentage of fertilized oocytes. No significant con-
founders were found for the correlations between tHcy, B-vitamins and the occurrence of 
pregnancy. The correlations in Table 3 are adjusted for significant confounders.
In addition, for tHcy, folate, cobalamin and PLP the concentration per oocyte was calcu-
lated and Spearman correlation coefficients were calculated between the concentration 
of tHcy and B-vitamins per oocyte and IVF-outcome. There was a weak, but statistically 
significant inverse correlation between the concentration of tHcy per oocyte and the 
occurrence of biochemical pregnancy (odds ratio = 0.56, 95% CI 0.34-0.95, P < 0.05).
DisCussion
This study demonstrates for the first time an inverse correlation between tHcy concentra-
tions in follicular fluid, the number of retrieved oocytes and the occurrence of biochemical 
pregnancy in women undergoing IVF or ICSI-treatment. Homocysteine is a thiol known to 
induce the release of reactive oxygen species (ROS) that are scavenged by endogenous 
glutathione. ROS is important for oocyte maturation and fertilization. However, high levels 
of ROS may induce apoptosis of oocytes resulting in a lower number. In addition, high ROS 
in the culture medium of embryos have been shown to result in low cleavage rates, high 
embryonic fragmentation and low rates of blastocyst formation (16). Our findings are also 
Table 2. Spearman rank correlation coefficients (r) between tHcy and B-vitamins per gram of protein in 
follicle fluid
tHcy (μmol/g)
rP
Folate (nmol/g)
rP
Cobalamin (pmol/g)
rP
Folate (nmol/g) -0.29 (0.002)
Cobalamin (pmol/g) -0.16 (0.066) 0.25 (0.007)
Pyridoxine (nmol/g) -0.20 (0.020) 0.26 (0.002) 0.13 (0.154)
Table 3. Adjusted correlations coefficients ( 95% confidence interval (CI)) and odds ratios (95% CI) 
between tHcy and B-vitamins in follicle fluid and IVF/ICSI outcome in 143 women
Number of oocytes
correlation coefficients
(95% CI) (SE)
Fertilization rate
correlation coefficients 
(95% CI) (SE)
Pregnancy rate
Odds Ratios
(95% CI) (SE)
tHcy (μmol/g) -0.16* (-0.31 - -0.01) (0.08) -0.02 (-0.17 – 0.14) (0.08) 0.49 (0.17-1.38) (0.53)
Folate (nmol/g)  0.05 (-0.12 - 0.23) (0.09) -0.04 (-0.22 – 0.15) (0.09) 0.67 (0.14 – 3.17) (0.80)
Pyridoxine (nmol/g)  0.01 (-0.15 - 0.18) (0.08) -0.11 (-0.27 – 0.06) (0.08) 1.06 (0.61 – 1.84) (0.23)
Cobalamin (pmol/g)  0.03 (-0.14 - 0.20) (0.09) -0.00 (-0.17 – 0.17) (0.08) 1.58 (0.67 – 3.71) (0.44)
SE = standard error. The correlations between tHcy, B-vitamins and number of oocytes are adjusted for 
age and the type of treatment (IVF or ICSI). The correlations between tHcy, B-vitamins and proportion of 
fertilized oocytes are adjusted for female factor subfertility.
 * P < 0.05
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in line with the recently reported inverse correlation between the tHcy concentration in 
follicular fluid, seminal plasma and embryo quality (13). Moreover, the inverse correlation 
between follicular fluid tHcy concentration and oocyte maturity reported by Szymanski 
and Kazdepka-Zieminska supports our data (12). Therefore, the homocysteine pathway 
and tHcy in particular may play a role in gametogenesis and follicle development, which 
confirms our hypothesis that hyperhomocysteinaemia is detrimental to the quality of the 
oocyte and subsequent fertilization and pregnancy.
The unadjusted tHcy and B-vitamin concentrations are slightly higher compared with 
the concentrations measured in our previous study (11). Besides the larger study group 
of the current study, this may also be explained by changes in dietary intake and lifestyle 
during the last fifteen years. Another explanation may be a difference in the amount of 
flushing medium that was used in each study. However, the adjusted follicular fluid con-
centrations of tHcy in the present study are comparable with the adjusted concentrations 
recently reported by Ebisch et al. (13).
During the sixties and seventies, several small studies and case reports already reported 
an association between female subfertility and cobalamin deficiency. The described 
women became pregnant within a year after vitamin B12 administration (17-21). In the 
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Figure 1. Correlation between logtransformed tHcy concentrations in follicular fluid and the number of 
oocytes retrieved per woman. 
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present study cobalamin concentrations in follicular fluid were not correlated with any of 
the fertility outcome parameters. This may be explained by the absence of severe cobala-
min deficient participants.
Some strengths and weaknesses of the study have to be addressed. The study group 
was homogenous with respect to the inclusion of subfertile couples only. However, the 
group is heterogeneous with regard to the causes of subfertility. We did not determine 
the vitamins and tHcy concentrations in blood, because the aim was to study the closest 
environment of the oocyte. Moreover, significant correlations between serum tHcy, folate, 
cobalamin and follicular fluid concentrations have been reported before (11). A strong 
finding is that the correlations between tHcy and the B-vitamins in follicular fluid are 
comparable with the correlations in blood.
In this study, we pooled the follicular fluid samples from all aspirated follicles and there-
fore we can only present general correlation coefficients between tHcy and the B-vitamin 
concentrations and fertility outcome parameters. Studies in animals reported a change of 
follicular fluid composition during follicular growth and maturation and it is feasible that 
B-vitamins and tHcy concentrations differ between follicles (22, 23). In future studies it 
would be preferable to measure concentrations in the separate follicles and to correlate 
them with the development and outcome of that specific oocyte.
Our study indicates that the homocysteine pathway, in which B-vitamins and methi-
onine as nutrients are involved, plays a significant role in fertilization and the occurrence 
of early pregnancy. Because nutrition is part of lifestyle it is amenable for intervention. 
Therefore, more studies should focus on possible beneficial effects of nutritional interven-
tion in the treatment of subfertility.
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Chapter 4
Homocysteine metabolism in 
the pre-ovulatory follicle during 
ovarian stimulation
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aBsTraCT
Background: Ovarian stimulation gives rise to supraphysiological estradiol levels, which 
may affect oocyte quality. This study aims to investigate whether ovarian stimulation 
deranges the homocysteine pathway thereby affecting the pre-ovulatory follicle.
methods: Blood samples were collected on cycle day 2 and the day of hCG administration 
in 181 women undergoing ovarian stimulation for IVF. In each subject the diameter of 
the two leading follicles was measured and the corresponding follicular fluids were col-
lected. In blood and follicular fluid samples total homocysteine (tHcy), folate, cobalamin 
and pyridoxal’5-phosphate (PLP) were determined. According to the blood folate levels, 
women were classified as either folic acid supplemented (n = 113) or non-supplemented 
(n = 32).
results: Ovarian hyperstimulation resulted in a significant decrease in blood tHcy and 
cobalamin levels (both P ≤ 0.001). The blood concentrations of tHcy, folate, cobalamin and 
PLP were significantly correlated with the corresponding follicular fluid concentrations 
(all P ≤ 0.001). Follicular fluid tHcy concentrations were inversely correlated with follicular 
diameter (P ≤ 0.05). In folic acid supplemented women, follicular fluid folate was inversely 
correlated with follicular diameter (P ≤ 0.05).
Conclusions: Ovarian hyperstimulation deranges blood and follicular fluid biomarkers of 
the homocysteine pathway. High ovarian follicular fluid tHcy and folate levels may have 
detrimental effects on follicular development.
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inTroDuCTion
Involuntary childlessness imposes a heavy burden on most subfertile couples (1, 2). Many 
couples therefore seek help by means of artificial reproduction techniques such as in vitro 
fertilization (IVF) to achieve pregnancy. While these techniques have improved the treat-
ment of subfertile couples, the chance of achieving a clinical pregnancy remains around 
25% per started cycle (3). In order to obtain multiple embryos from which to select for 
transfer to the uterus, exogenous gonadotrophins are administered to stimulate multi-
follicular development in the ovaries. This results in supraphysiological serum levels of 
gonadotrophins and estradiol which themselves may have a detrimental effect on oocyte 
and embryo quality (4) Although the mechanisms of this effect remain to be elucidated, 
derangement of intrafollicular homocysteine pathway may be involved. Mild to moderate 
hyperhomocysteinemia is associated with detrimental effects on reproductive outcome, 
ranging from congenital malformations and miscarriages to pregnancy induced hyper-
tension and low birth weight (5-7). The main causes of hyperhomocysteinemia include a 
dysbalance between the intake of folate, cobalamin, pyridoxine and methionine, meta-
bolic derangements and related genetic variations (8).
Exogeneous estrogens have been shown to affect several endocrine and metabolic 
pathways in women, including homocysteine metabolism. For instance, artificial estrogen 
treatment of postmenopausal women significantly lowers the total homocysteine (tHcy) 
levels (9). Further evidence for sex steroid modulation of tHcy levels comes from studies 
showing levels to be significantly lower in the luteal phase than in the follicular phase 
of the normovulatory cycle (10). Moreover, blood tHcy levels decrease during pregnancy 
from preconception onwards (11-13).
Whether estrogens affect the homocysteine pathway directly and/or via intermediates 
and cofactors is not clear. In some studies, a significant decrease of pyridoxine (14) or 
cobalamin (15) was observed in postmenopausal women taking estradiol supplements, 
but this could not be confirmed by others (14, 16).
Given the previously described detrimental effects of hyperhomocysteinaemia on 
embryo quality (17), suppression of tHcy concentrations by increasing estradiol levels 
might be expected to have a beneficial effect. However, recent data has indicated that 
supraphysiological estradiol levels are correlated to higher levels of embryo aneuploidy 
(18) suggesting a negative effect on oocyte quality. At present, little is known about the 
influence of ovarian hyperstimulation treatment on the homocysteine pathway in the 
direct environment of the maturing follicle and oocyte in human, or the relationship 
between follicular tHcy concentrations and follicular growth. Moreover, the extent to 
which folate supplementation modifies these relationships is not known. Therefore, the 
principal aims of the present study were to investigate the influence of ovarian stimulation 
with exogenous gonadotropins on the levels of biomarkers of the homocysteine pathway 
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in blood and the follicular fluid of the maturing oocyte, and to study the correlations 
between the levels of these biomarkers and the follicular diameter. Finally, the impact of 
periconception folate supplementation on these correlations was determined.
maTeriaLs anD meThoDs
Population
The FOod, Lifestyle and Fertility Outcome-study (FOLFO-study) is a periconception cohort 
study focused on the influence of the preconception health of the couple on fertility 
parameters and pregnancy outcome. Between September 2004 and October 2006 sub-
fertile couples undergoing an IVF with or without intracytoplasmic sperm injection (ICSI) 
procedure at the Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, 
were invited to participate. Exclusion criteria were oocyte donation cycles, the diagnosis 
of endometriosis or hydrosalpinx and age above 43 years. Seventy-four percent of eligible 
couples consented to participate in the study. Data from these women have not been 
previously published. All obtained materials and questionnaires were processed anony-
mously. The study protocol was approved by the Dutch Central Committee for Human 
Research (CCMO) and the Medical Ethical and Institutional Review Board of the Erasmus 
MC, University Medical Centre in the Netherlands.
In vitro fertilization procedure
All women started daily subcutaneous injections of 150 IU recombinant FSH, on the sec-
ond day of a spontaneous cycle (Puregon®, NV Organon, Oss, The Netherlands or Gonal-F®, 
Serono Benelux BV, The Hague, The Netherlands). Daily subcutaneous administration of 
0.25 mg GnRH antagonist (Orgalutran®, NV Organon, or Cetrotide®, Serono Benelux BV) 
was started when at least one follicle measured ≥14 mm. To induce final oocyte matura-
tion, a single dose of 5,000 or 10,000 IU human chorionic gonadotrophin sc (hCG, Pregnyl®, 
NV Organon) was administered as soon as the largest follicle reached at least 18 mm in 
diameter and at least 1 additional follicle of > 15 mm was present. Oocyte retrieval was 
carried out 35 hours after hCG injection by transvaginal ultrasound-guided puncture 
of the follicles. Immediately prior to this procedure, the diameter of the leading follicle 
in both the right and left ovary was measured in three dimensions. Fluid from each of 
these two follicles was aspirated and stored separately before continuing with the oocyte 
retrieval procedure. After oocyte retrieval the follicular fluid samples were centrifuged 
for 10 minutes at 1,700 x g to separate red blood cells, leucocytes and granulosa cells. 
The samples were frozen without preservatives and stored at –20°C until assayed. Venous 
blood samples were drawn from each woman on cycle day 2 and the day of hCG adminis-
tration. At both time points tHcy, folate, cobalamin, pyridoxine, total protein and estradiol 
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were determined. In addition, on cycle day 2, FSH was determined. Blood was collected in 
dry vacutainer tubes, ethylenediamine tetra-acetate (EDTA) containing vacutainer tubes 
and lithium heparin containing vacutainers.
 After clotting, the blood collected in dry vacutainer tubes was centrifuged at 
2,000 x g and the sera were stored at 4°C before being assayed. The venous blood samples 
collected in the EDTA containing vacutainer tubes were kept on ice for a maximum of one 
hour after which the plasma was separated after centrifugation and stored at 4°C before 
being assayed. Blood samples drawn into lithium heparin containing vacutainers were 
stored at 4°C before being assayed.
tHcy in EDTA plasma and follicular fluid and pyridoxine as pyridoxal’5-phosphate 
(PLP) in whole blood and follicular fluid were determined using high-performance liquid 
chromatography with reversed phase separation and fluorescence detection (19, 20). For 
the determination of folate and cobalamin an immunoelectrochemoluminescence immu-
noassay was used (Roche Modular E170, Roche Diagnostics GmbH, Mannheim, Germany). 
For the determination of red blood cell (RBC) folate, 100 μL blood out of one EDTA tube 
was hemolyzed with 2 mL freshly prepared ascorbic acid (0.05g ascorbic acid in 25 mL 
aqua dest) directly after blood sampling. Subsequently, the hematocrit of the EDTA-blood 
was determined on a Sysmex XE-2100 (Groffin Meyvis, Etten-Leur, The Netherlands). The 
hemolysate was centrifuged for 10 minutes at 2,000 x g shortly before the folate measure-
ment. The folate concentration in the hemolysate was calculated in RBC folate using the 
following formula: (nmol hemolysate folate * 21) - (nmol/L serum folate * (1- hematocrit)) 
/ hematocrit = nmol/L RBC folate. Total protein concentrations were determined photo-
metrically on a Hitachi 917 (Roche Diagnostics GmbH, Mannheim, Germany). Levels of FSH 
were measured by luminescence-based immunometric assay (Immulite 2000, Diagnostic 
Products Corporation, Los Angeles, USA). Estradiol was measured using coated tube radio-
immunoassay obtained from the same supplier.
Inter-assay coefficients of variation for tHcy were 4.8% at 14.6 µmol/L and 3.3% at 34.2 
µmol/L, for folate 4.5% at 13 nmol/L and 5.7% at 23 nmol/L, for cobalamin 3.6% at 258 
pmol/L and 2.2% at 832 pmol/L, for PLP 1.8% at 40 nmol/L and 1.3 % at 115 nmol/L, for 
total protein 1.5% at 55 g/L and 1.3% at 84 g/L, for FSH <5.8% and for estradiol <8.8%. The 
detection limit for tHcy was 4 µmol/L, for folate 1.36 nmol/L, for cobalamin 22 pmol/L, for 
pyridoxine 5 nmol/L, for total protein 0.1 g/L, for FSH 0.1 U/L, and for estradiol 10 pmol/L.
Questionnaires
After oocyte retrieval, women filled out a general questionnaire from which the follow-
ing data were extracted: medical history, body length and weight, ethnicity, and lifestyle 
factors, such as smoking and the use of vitamin supplements. Ethnicity was classified 
according to the definitions of Statistics Netherlands (21).
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Women were considered to be taking folic acid supplements when folate levels in 
serum were > 22.4 nmol/L on both cycle day 2 and the day of hCG administration (22).
Statistical Methods
Follicular fluid total protein concentrations vary with follicular maturity (23). Concentra-
tions of tHcy and B-vitamins in follicular fluid are therefore also expressed in concentration 
per gram of protein. The results were expressed in median (range), because of the skewed 
distributions of tHcy, B-vitamins, FSH and estradiol. Consequently these variables were 
log transformed before statistical testing. Because the distribution was normal after log 
transformation, paired t-tests were performed to determine differences between bio-
marker concentrations on cycle day 2 and the day of hCG administration and to determine 
differences between biomarker concentrations in blood and follicular fluid. Pearson’s cor-
relation coefficients were calculated to determine correlations between the deltas of the 
estradiol, tHcy, and B-vitamin concentrations.
In most subjects, but not all, two monofollicular fluid samples were obtained. In order 
to avoid a possible statistical bias arising from subjects producing just one fluid sample, 
a mixed model analysis was performed to determine correlations between the biomarker 
concentrations in blood and follicular fluid, and the diameter of the follicles. An indepen-
dent t-test was performed with one follicle per women to determine differences between 
biomarkers in follicular fluid of supplemented and non-supplemented women. A P-value 
of ≤ 0.05 was considered statistically significant. All statistical analyses were performed 
using SPSS 14.0 for Windows software (SPSS Inc., Chicago, Il, USA).
resuLTs
The flow chart of the study is presented in Figure 1 and the baseline characteristics of 
the participating women are given in Table 1. Of the 216 included couples, 10 dropped 
out before commencing the study. Five women conceived spontaneously before the start 
of IVF treatment, and 5 were diagnosed with a visible endometrioma or hydrosalpinx at 
the start of the IVF treatment. Four couples were excluded from analysis due to incorrect 
use of the IVF-medication, and one couple withdrew. In the remaining 201 couples, treat-
ments were cancelled before oocyte retrieval due to a poor response (n = 16), the threat of 
ovarian hyperstimulation syndrome (OHSS) (n = 3) and the occurrence of ovulation before 
oocyte retrieval (n = 1). The mean number of follicles > 10 mm measure on the day of hCG 
administration was 8 (SD 5) and the mean number of retrieved oocytes was 7 (SD 5). In 
4 cases, blood samples were not taken at the correct day. Consequently, 177 cycle day 2 
blood samples and 177 samples taken on the day of hCG administration were available 
for analysis.
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Figure 1. Flowchart of the study
Included
n = 216
Drop out (n = 15)
Conceived before starting treatment n = 5 
Visible endometrioma on ultrasound  n = 4 
Medication error n = 4
Visible hydrosalpinx on ultrasound     n = 1 
Couple withdrew n = 1
Cancelled before oocyte retrieval (n = 20)
Poor response n = 16
Threat of OHSS                 n = 3
Ovulation before oocyte retrieval n = 1
Non folic acid supplemented women
n = 32
Oocyte retrieval
n = 181
Monofollicular fluids
n = 175
Monofollicular fluids
n = 279
Folic acid supplemented women
n = 113
Monofollicular fluid
n = 51
 
Women were considered to be taking folic acid supplements when folate levels in serum were greater 
than 22.4 nmol/L on both cycle day 2 and the day of hCG administration (22). In 24 women of the 
included 181 women, serum concentrations indicated an irregular folic acid intake.
Table 1. Characteristics of the study subjects (n = 181)
Age (years) median (range) 36 (23.7 – 43.7)
Body Mass Index, kg/m2, median (range) 23.1 (16.1 – 36.3)
Ethnicity:
Dutch % (n)
Non-Dutch European % (n)
Non-European % (n)
72
8.9
19.1
(113)
 (14)
 (30)
Folic acid containing supplement, yes % (n) 87.2 (143)
Smokers % (n) 9 (15)
Duration of subfertility, median (range) 36 (4-121)
Cause of subfertility:
18.2
44.2
8.3
29.3
(33)
(80)
(15)
(53)
Female factor % (n)
Male factor % (n)
Male and female factor % (n)
Idiopathic % (n)
Baseline FSH (U/L), cycle day 2, median (range) 8.3 (0.4 – 30.3)
Baseline estradiol (pmol/L), cycle day 2, median (range) 137 (41 – 307)
Ethnicity was classified according to the definitions of Statistics Netherlands (http://www.cbs.nl/en-GB/
default.htm 2007)
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Of the 299 collected monofollicular fluid samples, 20 samples were excluded from 
analysis due to contamination with the culture medium, which contains very high concen-
trations of cobalamin (> 14000 pmol/L) and folate (> 950 nmol/L). The mean diameter of 
the follicles from which fluid was collected was 19.2 mm (SD 2.8 mm). This mean diameter 
was similar in the subgroups of folic acid supplemented and non-supplemented. More-
over, no significant differences were observed between young and old participants (19.0 
vs 19.4 in the subgroups of ≤ and > 36 years, respectively).
Blood and follicular fluid concentrations of estradiol, total protein and biomarkers of 
the homocysteine pathway are presented in Table 2. One hundred and thirteen women 
(67%) were classified as folic acid supplement users, with median folate concentrations of 
36.4 nmol/L (range 22.9 – 908.0) on cycle day 2 and 38.8 nmol/L (range 22.8 – 174.3) on the 
day of hCG administration. Thirty two women (19%) were classified as non-supplemented, 
with median folate concentration of 14.8 nmol/L (range 6.4 – 20.7) on cycle day 2, and 
15.3 nmol/L (range 6.6 – 22.3) on the day of hCG administration. The median age of non-
supplemented and supplemented women was not significantly different. In folic acid 
non-supplemented women, subfertility was more often caused by both a female and a 
Table 2. Biomarkers in blood and follicular fluids, and the correlations between the biomarkers in blood 
and follicular fluids
Blood Follicular fluid
Cycle day 2
(n = 177)
hCG day
(n = 177)
Diff.a
concentration
(n = 279)
protein ratiob
(n = 279)
estimatec
Estradiol 
(pmol/L)
136.5 (41 – 307) 2137 (233 – 11978) *
tHcy 
(μmol/L)
9.1 (5.0 – 75.3) 8.4 (4.3 – 71.6) * 6.6 (0.9 – 73.6) 0.12 (0.03 – 1.27) 0.98*
Folate 
(nmol/L)
30.5 (6.4 – 908.0) 32.6 (6.6 – 174.3) 29.8 (5.9 – 234.2) 0.55 (0.11 – 4.04) 0.73*
Folate RBC 
(nmol/L)
1407 (459 – 3611) 1347 (427 – 4413)
Cobalamin 
(pmol/L)
319 (74 – 1856) 303 (75 – 1046) * 208 (59 – 1136) 3.81 (1.02 – 34.42) 0.87*
Pyridoxine 
(nmol/L)
80 (32 – 310) 76 (35 – 310) 72 (2 - 310) 1.37 (0.03 – 5.85) 1.18*
Total protein 
(g/L)
72 (58 – 84) 71 (59 – 83) * 57 (21 – 70)
Note: values are given as median (range).
a Diff. = difference between serum concentrations at cycle day 2 and the day of hCG administration;
b follicular fluid concentrations of B-vitamins and tHcy expressed per gram total protein;
c Mixed model analysis with 2log transformed biomarker concentrations; correlations between 
concentration in blood on the day of hCG administration and the corresponding concentration per gram 
total protein in follicular fluid.
Folate RBC = red blood cell folate
* P ≤ 0.001
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male factor compared to the supplemented women (28% versus 3%) (P ≤ 0.01). Other 
causes for subfertility were not significantly different between these two subgroups. In 
the remaining 24 women, serum concentrations reflected sporadic folate intake, and the 
associated data was considered non-informative in this case.
Samples taken following ovarian stimulation (on the day of hCG administration) 
revealed tHcy concentrations to be significantly lower in follicular fluid than in blood. 
Women taking folic acid supplementation had significantly lower follicular fluid levels 
of tHcy, median 6.4 μmol/L (range 3.5 - 73.6 μmol/L) than non-supplemented women, 
median 7.1 μmol/L, (range 4.0 - 47.0) (P ≤ 0.005). Folate concentrations were also observed 
to be consistently higher in blood than in follicular fluid. Folate concentrations in follicular 
fluid were significantly higher in supplemented women, median 35.8 nmol/L (range 
13.0 - 234.2) compared with non-supplemented women, median 15.1 nmol/L (range 6.3 
- 39.8) (P ≤ 0.001). Cobalamin and pyridoxine concentrations were also significantly lower 
in follicular fluid than in blood (P ≤ 0.001). All biomarker concentrations in blood were 
significantly correlated with follicular fluid levels (all P ≤ 0.001) (Table 2).
During ovarian stimulation, serum estradiol concentrations significantly increased 
and blood tHcy, cobalamin and total protein levels all decreased significantly (Table 2). 
However, no significant correlations were found between the increase of the estradiol 
concentrations and the change in those biomarker concentrations in the blood. Likewise, 
the increase of the estradiol concentrations were not correlated with the biomarker con-
centrations in follicular fluid.
In the group as a whole, a significant inverse correlation between follicular fluid tHcy 
protein ratio and the follicular diameter was demonstrated (Table 3). A two-fold increase of 
the tHcy concentration was associated with a 0.06 mm decrease of the follicular diameter 
(P ≤ 0.05). In non-supplemented women this inverse correlation was much stronger (1.64 
mm; P ≤ 0.01). In supplemented women a two-fold increase of the follicular folate concen-
tration was associated with a 0.74 mm decrease of the follicular diameter (P ≤ 0.05).
Table 3. Correlations between follicular fluid biomarker concentrations and follicular diameter stratified 
for folic acid supplement use
Total group
(n = 279 samples)
Supplement use
(n = 175 samples)
Non-supplement use
(n = 51 samples)
tHcy (μmol/g) -0.06 s.* -0.15 n.s. -1.64 s.**
Folate (nmol/g) -0.17 n.s. -0.74 s.* 0.44 n.s.
Cobalamin (pmol/g) 0.49 n.s. 0.49 n.s. 0.25 n.s.
Pyridoxine (nmol/g) 0.29 n.s. 0.17 n.s. 0.73 n.s.
Correlations of Mixed Model Analysis are given as estimate and P-value; n.s. = not significant;
s. = significant; * P ≤ 0.05; ** P ≤ 0.01
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DisCussion
This study demonstrates that ovarian hyperstimulation in women undergoing IVF treat-
ment is associated with a decrease of tHcy and cobalamin levels both in blood and in 
follicular fluid. Furthermore, inverse correlations are shown between follicular fluid tHcy 
and folate concentrations, and follicular diameter.
The observed decline in blood levels of tHcy and cobalamin levels during ovarian hyper-
stimulation treatment may be due to estradiol mediated induction of general enzyme 
activity through which the metabolization and clearance of both biomarkers might be 
increased. Two smaller studies reported no significant effect of ovarian hyperstimulation 
on biomarkers of the homocysteine pathway (24, 25). However, the inverse effect of rising 
estradiol levels on tHcy concentration is consistent with the results of studies compar-
ing pre- and post-menopausal women (26, 27) and trials in which the administration of 
estrogen was compared with placebo in post-menopausal women (9, 14, 28). Similarly, a 
decrease in the cobalamin levels in estrogen supplemented post-menopausal women has 
been recently demonstrated (15).
In the present study, the concentration of tHcy in follicular fluid was inversely correlated 
with the follicular diameter. Since tHcy levels were adjusted for maturation by calculating 
the protein ratio (23), our data suggests that exposure of the follicles to high blood con-
centrations of tHcy may contribute to restricting follicular growth. The strong correlations 
between tHcy in blood and follicular fluid and the stronger correlation between tHcy and 
follicular diameter in non-supplemented women are consistent with this observation. Pre-
viously, our group demonstrated a positive correlation between tHcy in follicular fluid and 
follicular diameter (29). The levels of tHcy in follicular fluid in that study and the present 
study were similar. The discrepancy in results may reflect the small number of samples in 
our previous study.
On the basis of the present findings, it is not possible to determine whether high tHcy 
levels in follicular fluid are the cause or result of limited follicular growth. However, the 
present findings are consistent with our previously reported observation that a high tHcy 
in follicular fluid reduces embryo quality (17) and other reported associations between 
mild to moderate hyperhomocysteinemia and detrimental effects on reproductive out-
come (5-7).
The toxic effects of tHcy may be due to the production of reactive oxygen species 
(ROS). A certain level of ROS in follicular fluid is necessary for oocyte maturation (30) and 
ovulation (31). Moreover, in a previous study, patients who became pregnant after IVF 
had significantly higher levels of ROS in their follicular fluid compared to non-pregnant 
women (32, 33). An excess of ROS results in a state of oxidative stress. High levels of ROS 
in culture medium of embryos are associated with low cleavage rates and high embryonic 
fragmentation rates (34). The results of our study seem to suggest that high levels of tHcy 
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have a detrimental effect on follicular maturation as reflected by the follicle diameter. This 
may be a consequence of oxidative stress. The decline of blood tHcy concentrations dur-
ing ovarian hyperstimulation may suggest a beneficial effect of this hormonal treatment 
on follicle maturation. However, it is plausible that there is an optimal level of tHcy.
In the present study, a detrimental effect of both low and high folate levels on follicular 
growth is suggested. Folate supplementation appeared to protect follicular growth against 
the observed detrimental effects of high tHcy levels. Folic acid supplementation lowers 
tHcy levels by remethylation of tHcy into methionine. Surprisingly, we also observed that 
rising folate levels in follicular fluids of folic acid supplemented women, median 35.8 
nmol/L, are associated with a significant smaller follicular diameter. There is an ongo-
ing discussion about possible adverse effects of excessive folate levels with respect to 
increased twinning rates (35-37). Our results are consistent with the previously proposed 
concept of an ‘optimal’ level of supplementation above which reproductive outcomes may 
deteriorate. Such a concept would also reconcile two apparently contradictory observa-
tions: that supraphysiological estradiol concentrations are associated with suppression of 
tHcy concentrations in the follicle, yet may be detrimental to oocyte and embryo quality. 
It would appear that excessive suppression of tHcy levels by high estrogens may indeed 
be harmful to gamete and embryo quality.
Some limitations of this study have to be addressed. Our own study lacks a control 
group, because follicular fluid is not available from spontaneous cycles. There is little data 
about the spontaneous cycle, and only a decline of tHcy has been reported before (10). 
However, the extent of tHcy decrease as reported by Tallova et al., cannot be compared 
with the present results because of the different timing of sampling. The women recruited 
for the present study constitute a heterogeneous group in terms of race, age and indication 
for treatment. The effect of ovarian stimulation treatment on tHcy, folate, cobalamin and 
pyridoxine and the associations between the same biomarkers and follicular diameter may 
be more prominent in certain subgroups. However, the aim of our study was to investigate 
this in a representative population of women undergoing IVF or ICSI. The strength of our 
study is the standardised design, the large sample size and the biomarkers determined 
in blood and monofollicular fluids. Moreover, all participants were treated according to 
the same ovarian stimulation protocol. Future studies should address possible associa-
tions between nutritional biomarker concentrations in the follicle and serum, and clinical 
outcomes of IVF. Moreover, maternal gene polymorphisms involved in the homocysteine 
pathway have also been associated with an increased risk of offspring with Down syn-
drome possibly due to chromosomal damage (38-40). The findings of the present study 
indicate that further studies are required to address whether polymorphisms may also be 
associated with follicular growth.
In conclusion, ovarian stimulation resulted in a significant decline in tHcy and cobala-
min blood concentrations but did not affect folate or pyridoxine levels. Follicular fluid tHcy 
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concentrations were inversely correlated with follicular diameter, and this association was 
much stronger in women who did not use a folic acid supplement. In folic acid supple-
mented women, follicular folate concentrations were inversely correlated with follicular 
diameter. This suggests that both high tHcy and high folate concentrations may be detri-
mental for follicular growth. This supports the need for finding the optimal folic acid dose 
not only to prevent neural tube defects but also to improve the quality of oogenesis.
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aBsTraCT
Background: Maternal hyperhomocysteinemia is detrimental for reproduction, but the 
effects on embryo quality are unknown. The aim of this study was to investigate whether 
biomarkers of the homocysteine pathway are associated with IVF outcome.
methods: In a prospective study we investigated associations between biomarkers of 
the homocysteine pathway and embryo quality and biochemical pregnancy in women 
undergoing IVF- or ICSI-treatment (n = 181). In the treatment cycle blood and monofol-
licular fluid samples were collected for determination of folate, cobalamin, and total 
homocysteine (tHcy) concentrations.
results: Sixty-seven percent of the women used folic acid supplements. In blood, a sig-
nificant correlation was established between high cobalamin and better embryo quality 
(standardized adjusted regression coefficient: – 0.17; 95% CI: -0.30, -0.01). In monofollicular 
fluid of non-supplemented women, high cobalamin correlated with better embryo quality 
(estimate: -0.87; 95% CI: -1.68, -0.06) whereas high tHcy resulted in poor embryo quality 
(estimate: 1.01; 95% CI: 0.08, 1.95). In monofollicular fluid of supplemented women high 
tHcy correlated with better embryo quality (estimate: -0.58; 95% CI: -1.12, -0.04). In the 
total group, a two-fold increase of monofollicular fluid folate corresponded with a 3.3 
higher chance (95% CI: 1.09, 9.71) to achieve pregnancy.
Conclusions: An optimal homocysteine pathway in follicular fluid are associated with a 
better embryo quality and chance of pregnancy.
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inTroDuCTion
In most couples who face difficulties in conceiving, the subfertility is considered to have a 
multifactorial origin. Whereas genetic causes are difficult to modulate, environmental and 
lifestyle factors also implicated in subfertility are potentially amenable to curative or pre-
ventive measures. Nutrition is an important remediable factor, but continues to be largely 
neglected when counselling and managing subfertile couples. In recent years, interest 
has increased in the role of folate and cobalamin as modulators of fertility outcome (1, 
2). These B vitamins have a central role in the homocysteine (tHcy) pathway. Shortages of 
folate and vitamin B12 result in hyperhomocysteinemia, which is associated with a num-
ber of adverse pregnancy outcomes, such as recurrent miscarriages, pregnancy induced 
hypertension and abruptio placentae (3-5). Hyperhomocysteinemia is also associated 
with the occurrence of several congenital malformations, such as neural tube defects, 
orofacial clefts and congenital heart disease (6-10). This has led to the recommendation 
of periconception folic acid supplementation and, in some countries, even to folic acid 
fortification of flour. Recently, our group demonstrated also a detrimental effect of high 
tHcy in ejaculated sperm and follicular fluid on embryo quality (11).
A low cobalamin status has also been associated with a higher risk of neural tube 
defects, oral facial clefts, congenital heart disease and spontaneous abortions (12-16). 
Furthermore, several studies and case reports suggest an association between cobalamin 
deficiency and female subfertility (17, 18).
Assisted reproductive technologies provide the opportunity to study the effects of 
biomarkers of nutrients in follicular fluid on fertility treatment outcomes, such as embryo 
quality. Follicular fluid offers a window on the intimate environment of the developing 
cumulus-oocyte complex that can easily be obtained during in vitro fertilization (IVF) 
treatment. Our group previously demonstrated significant correlations between folate, 
cobalamin and total homocysteine (tHcy) in blood and follicular fluid (19). Moreover, 
follicular fluid folate concentrations have been demonstrated to be higher in folic acid 
supplemented women while tHcy concentrations are lower (20, 21).
From this background we aimed to investigate whether the concentrations of tHcy and 
the intermediates folate and cobalamin in blood and follicular fluid are associated with 
embryo quality and the chance of achieving biochemical pregnancy in couples undergo-
ing IVF treatment with or without intracytoplasmic sperm injection (ICSI).
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maTeriaLs anD meThoDs
Study population
The FOod, Lifestyle and Fertility Outcome-project (FOLFO-project) was set up to study 
the influence of preconception nutrition and lifestyle on fertility and pregnancy outcome. 
Between September 2004 and October 2006, 292 subfertile couples undergoing an IVF 
procedure with or without ICSI at the tertiary referral fertility clinic, the Erasmus MC, Uni-
versity Medical Centre, Rotterdam, The Netherlands, were invited to participate. Women 
diagnosed with endometriosis and women with a hydrosalpinx were excluded since these 
conditions detrimentally influence IVF outcome. In addition, couples undergoing oocyte 
donation could not participate. The study protocol was approved by the Dutch Central 
Committee for Human Research (CCMO) and the Medical Ethical and Institutional Review 
Board of the Erasmus Medical Centre in Rotterdam. Participants provided written informed 
consent and obtained materials and questionnaires were processed anonymously.
It has previously been demonstrated that in women of reproductive age using 250 μg 
folic acid per day for four weeks, serum folate concentrations increase to a mean value of 
22.5 nmol/L (22). To minimize bias, we defined folic acid supplement users as women hav-
ing a serum folate concentration on both cycle day two and the day of hCG administration 
above 22.5 nmol/L. Women with serum folate concentrations below this level at both time 
points were defined as non supplement users.
In order to investigate more precise whether concentrations of tHcy and B-vitamins in 
follicular fluid are correlated with the occurrence of biochemical pregnancy, additional 
analyses were performed in women with single embryo transfer of an embryo that devel-
oped out of a collected monofollicular fluid (‘FOLFO-ET’).
In vitro fertilization procedure
All women started the ovarian stimulation treatment with daily injections of 150 IU recom-
binant Follicle Stimulating Hormone (rFSH) sc on cycle day two (Puregon®, NV Organon, 
Oss, The Netherlands or Gonal-F®, Serono Benelux BV, The Hague, The Netherlands). 
Administration of daily sc Gonadotrophin Releasing Hormone (GnRH) antagonist (Orgalu-
tran®, NV Organon, or Cetrotide®, Serono Benelux BV) was started when at least one follicle 
was ≥14 mm, as described previously (23). To induce final oocyte maturation, a single dose 
of 5,000 or 10,000 IU human Chorionic Gonadotropin (hCG) sc (Pregnyl®, NV Organon) was 
administered as soon as the largest follicle reached at least 18 mm in diameter and at least 
one additional follicle of more than 15 mm was observed. Oocyte retrieval was carried 
out 35 hours after hCG injection by transvaginal ultrasound-guided aspiration of follicles. 
Luteal phase supplementation of 600 mg/day micronized progesterone intravaginally, 
was started on the evening following oocyte pick-up and continued for 12 days thereafter. 
On day three after oocyte pick up a maximum of two embryos were transferred.
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Sample collection and analyses
During oocyte retrieval follicle diameters were remeasured and monofollicular fluid from 
the leading follicle was aspirated from each ovary and collected separately. Oocytes iso-
lated from these monofollicular fluids were washed and transferred to a separate droplet 
of medium in order to monitor embryo quality. The monofollicular fluid samples were 
centrifuged for 10 minutes at 1,700x g to separate red blood cells (RBC), leucocytes and 
granulosa cells. The samples were frozen without preservatives and stored at –20°C until 
assayed.
Venous blood samples were drawn from each woman on cycle day two before the 
first injection of rFSH and at the day of hCG administration. Folate, cobalamin, tHcy, FSH, 
estradiol (E2) and AMH concentrations were determined. For the determination of folate, 
cobalamin and hormones venous blood samples were drawn into dry vacutainer tubes and 
allowed to clot. After centrifugation at 2,000 x g, serum was collected before being assayed. 
Blood serum and monofollicular fluid samples from each patient were analyzed during 
routine laboratory procedures for folate and cobalamin using an immunoelectrochemolu-
minescence assay (Roche Modular E170, Roche Diagnostics GmbH, Mannheim, Germany). 
Total protein concentrations in monofollicular fluid were determined photometrically on 
a Hitachi 917 (Roche Diagnostics GmbH, Mannheim, Germany). Serum concentrations of 
FSH were measured by luminescence-based immunometric assay (Immulite 2000, Diag-
nostic Products Corporation (DPC), Los Angeles, CA, USA) and E2 was determined using 
coated tube radioimmunoassay obtained from the same supplier. AMH concentrations 
were assayed using an in-house double antibody enzyme-linked immunosorbent assay 
(ELISA), commercially available through Diagnostic Systems Laboratories (Webster, TX).
For the determination of RBC folate and plasma tHcy, venous blood samples were drawn 
into ethylenediamine tetra-acetate (EDTA) containing vacutainer tubes. The EDTA-blood 
samples were placed on ice and within one hour plasma was separated by centrifuga-
tion for determination of tHcy. Homocysteine in EDTA plasma and monofollicular fluid 
was determined during routine laboratory procedures using high performance liquid 
chromatography with reversed phase separation and fluorescence detection (24). For the 
determination of RBC folate, 100 μL blood from an EDTA tube was hemolyzed with 2 mL 
freshly prepared ascorbic acid (0.05g ascorbic acid in 25 mL aqua dest), directly after blood 
sampling. Subsequently, the hematocrit of the EDTA-blood was determined on a Sysmex 
XE-2100 (Groffin Meyvis, Etten-Leur, The Netherlands). The hemolysate was centrifuged for 
10 minutes at 2,000 x g shortly before the folate measurement. The folate concentration in 
the hemolysate was calculated in RBC folate using the following formula: (nmol hemolysate 
folate * 21) - (nmol/L serum folate * (1- hematocrit)) / hematocrit = nmol/L RBC folate.
Inter-assay coefficients of variation for folate were 4.5 % at 13 nmol/L and 5.7 % at 23 
nmol/L, for cobalamin 3.6 % at 258 pmol/L and 2.2 % at 832 pmol/L, for tHcy 4.8 % at 14.6 
µmol/L and 3.3 % at 34.2 µmol/L, for total protein 1.5 % at 55 g/L and 1.3 % at 84 g/L, for 
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FSH these coefficients were < 5.8 %, for E2 < 8.8 %, and for AMH <10%. The detection limit 
for folate was 1.36 nmol/L, for cobalamin 22 pmol/L, for tHcy 4 µmol/L, for total protein 0.1 
g/L, for FSH 0.1 U/L, and for E2 10 pmol/L.
Questionnaires
In addition, on the day of oocyte pick up, participants were invited to fill out a general 
questionnaire from which the following data were extracted: medical history, height and 
weight, ethnicity, use of medication, and lifestyle factors, such as smoking and the use of 
vitamin supplements in the preceding month. Ethnicity was classified according to the 
definitions of Statistics Netherlands (25).
Major outcomes
The clinical endpoints of the study were embryo quality and the occurrence of biochemi-
cal pregnancy. On day three post oocyte retrieval embryo quality scores were assigned 
according to previously described criteria (26). These scores ranged from one (best quality) 
to five (poor quality and inadequate for embryo transfer). Biochemical pregnancy was 
determined by a urinary pregnancy test 15 days after oocyte retrieval.
Statistical analysis
Monofollicular fluid total protein concentrations vary with follicular maturity (27). Con-
centrations of tHcy and B-vitamins in monofollicular fluid are therefore expressed in 
concentration per gram of protein. Multiple linear and logistic regression analyses were 
performed forward to determine associations between tHcy, and B-vitamin concentrations 
in blood and the outcome parameters mean embryo score and biochemical pregnancy. 
In most subjects, two monofollicular fluid samples were obtained. In order to avoid a pos-
sible statistical bias arising from subjects producing just one fluid sample, a mixed model 
analysis was performed in which one or two samples per subjects could be analysed. With 
this analysis correlations between the concentrations of B-vitamins and tHcy in monofol-
licular fluid and embryo score and pregnancy were determined.
Age and smoking are major independent determinants of fertility outcome and there-
fore, were considered as potential confounders. In the analyses of biochemical pregnancy 
as outcome parameter the number of transferred embryos was included as additional 
potential confounder. Covariates were included as confounders in the model when the 
P-value was equal or less than 0.1.
In the subgroup of women with single embryo transfer of an embryo that developed 
from the oocyte derived of a collected monofollicular fluid (‘FOLFO-ET’), logistic regres-
sion analyses were performed to determine correlations between the concentrations of 
B-vitamin and tHcy in monofollicular fluid and the occurrence of pregnancy.
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A P-value of < 0.05 was considered statistically significant. All statistical analyses were 
performed using SPSS 14.0 for Windows software (SPSS Inc, Chicago, Il, USA).
resuLTs
Study population
Seventy-four percent of the eligible couples participated in the study (n = 216). Reasons 
for not participating were: couples not being prepared to spend time visiting the hospital 
and/or completing questionnaires, having a language barrier, or a doctor forgetting to 
ask for participation. Of these couples, 15 dropped out and 20 women did not undergo 
oocyte retrieval for reasons specified in figure 1. The baseline characteristics of the 181 
participating women are given in Table 1, along with overall treatment outcomes. Data on 
BMI, smoking and folic acid supplementation were missing in respectively 15, 14 and 17 
women. Eighty-seven percent of the participants reported the use of folic acid containing 
supplements (n = 143). Of these women 24% (n = 34) reported to use more than one folic 
acid containing supplement. However, in 113 women serum folate concentrations were 
consistent with a regular folic acid intake. In 32 women, serum concentrations indicated 
Figure 1. Flowchart of included couples
Included women
n = 216
Oocyte retrieval
n = 181
Embryo transfer
n = 165
Biochemical Pregnancy
n = 52 
Drop out (n = 15)
Pregnancy before start n = 5 
Visible endometrioma n = 4 
Medication error n = 4
Visible hydrosalpinx n = 1 
Couple withdrawn n = 1
Cancellation before oocyte retrieval (n = 20)
Poor respons n = 16
Imminent OHSS                 n = 3
Ovulation before oocyte retrieval n = 1
Monofollicular fluids
With oocyte:        n = 208
Without oocyte:   n = 71
SET of ‘FOLFO-embryo’:
n = 58
Biochemical pregnancy
after ‘FOLFO-ET’
n = 16
IVF: 64.1%
ICSI 35.9%
SET 82.4%
DET 17.6%
 
OHSS: Ovarian Hyper Stimulation Syndrome; SET: single embryo transfer; DET: double embryo transfer; 
FOLFO-ET: Single embryo transfer of an embryo that developed out of a collected monofollicular fluid
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that folic acid supplements had not been taken. In the remaining 24 women serum 
concentrations indicated an irregular folic acid intake. One or both blood samples were 
missing from 12 women.
Serum parameters
Day two blood samples of the treatment cycle from 177 women were available for analyses 
(Table 2). The results were expressed in median (range) because of the skewed distribu-
tions of FSH, E2, B-vitamins and tHcy. Consequently these variables were log-transformed 
before statistical testing.
In the total group and the subgroup of non-supplemented women a significant cor-
relation was established between a high cobalamin concentration in blood and a high 
mean embryo quality (low score) (standardized adjusted regression coefficient: – 0.17, 
95% confidence interval (CI): -0.30, -0.01 and standardized adjusted regression coefficient: 
– 0.39, 95% CI: -0.81, -0.00 respectively). Folate and tHcy concentrations in blood were not 
correlated with mean embryo quality and none of the B-vitamins or tHcy concentrations 
in serum was significantly correlated with the occurrence of biochemical pregnancy.
Biomarkers in monofollicular fluid
Of the 299 collected monofollicular fluid samples from 181 women, 20 samples from 14 
women were excluded from analysis due to contamination with culture medium, which 
itself contains very high concentrations of cobalamin (> 14000 pmol/L) and folate (> 950 
nmol/L). Of the remaining 279 monofollicular fluid samples, 208 contained one oocyte. 
The results are expressed in median (range) because of the skewed distributions and the 
variables were consequently log-transformed before statistical testing (Table 3).
Table 1. Baseline characteristics of the study population and overall treatment outcome (n = 181).
Age (years), mean (SD) 35.5 (4.4)
BMI (kg/m2), mean (SD) 23.9 (3.8)
Smoking, yes, % (no.) 9 (15)
Folic acid supplementation (questionnaire), yes, % (no.) 87.2 (143)
Folic acid supplementation (biochemistry), yes, % (no.) 66.9 (113)
Cause of subfertility: Female factor, % (no.)
 Male factor, % (no.)
 Male and female factor, % (no.)
 Idiopathic, % (no.)
18.2
44.2
8.3
29.3
(33)
(80)
(15)
(53)
FSH, cycle day two (U/L), median (range) 8.4 (0.4 – 30.3)
Estradiol, cycle day two (pmol/L), median (range) 136.5 (41 – 307)
AMH, cycle day two (μg/L), median (range) 2.1 (0.1 - 18.6)
Embryo score of fertilized oocytes, mean (SD) 2.7 (0.6)
Biochemical pregnancy per oocyte retrieval, % (no.) 29 (52)
SD, standard deviation.
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No correlations were found between B-vitamins and tHcy in follicular fluid and the qual-
ity of the corresponding embryo in the total group. However, higher tHcy concentrations 
in monofollicular fluid of supplemented women corresponded with better embryo quality 
(adjusted estimate: -0.58; 95% CI: -1.12, -0.04). In monofollicular fluid of non-supplemented 
women cobalamin and tHcy concentrations were significantly correlated with embryo 
quality of the corresponding follicle. Higher cobalamin concentrations in follicular fluid 
corresponded with a better embryo quality after adjustment for age (adjusted estimate: 
-0.87; 95% CI: -1.68, -0.06) while higher tHcy concentrations corresponded with a poorer 
embryo quality (adjusted estimate = 1.01, 95% CI: 0.08, 1.95).
In the subgroup of women with a single embryo transfer of an embryo derived from 
an individually aspirated and analyzed follicle (n = 58) cobalamin and tHcy were not 
correlated with the occurrence of biochemical pregnancy. However, after adjustment for 
age, a doubling in follicular folate concentrations increased the chance of biochemical 
pregnancy by a factor of 3.3 (95% CI: 1.09, 9.71) (Table 4). In this group, pregnant women 
were significantly younger compared to non-pregnant women (34 versus 37 years, P = 
0.02). Pregnant and non-pregnant women were not different in BMI, smoking, and serum 
concentrations of FSH, E2, AMH, folate, cobalamin and tHcy.
Table 3. Levels of the biomarkers of the homocysteine pathway in monofollicular fluid and associations 
with embryo quality.
Embryoscore d
Median c (range) Estimate e 95% CI
Total group (n = 
279 samples)
Folate (nmol/g) 0.55 (0.11-4.04) -0.10 -0.33, 0.12 1
Cobalamin (pmol/g) 3.81 (1.02-34.42) -0.05 -0.32, 0.22 1
tHcy (μmol/g) 0.12 (0.03-1.27) 0.07 -0.35, 0.48 1
Supplemented a
(n = 175 samples)
Folate (nmol/g) 0.64 (0.36-4.04) -0.04 -0.34, 0.26
Cobalamin (pmol/g) 3.91 (1.02-34.42) 0.04 -0.24, 0.33
tHcy (μmol/g) 0.12 (0.06-1.27) -0.58 -1.12, -0.04  *
Non-
supplemented b
(n = 51 samples)
Folate (nmol/g) 0.27 (0.11-0.63) -0.60 -1.50, 0.29
Cobalamin (pmol/g) 3.81 (1.65-7.00) -0.87 -1.68, -0.06 1 *
tHcy (μmol/g) 0.14 (0.07-0.80) 1.01 0.08, 1.95  *
CI, confidence interval.
* P = 0.04
a Supplemented: defined as women who had taken folic acid supplements based on serum folate 
concentrations on 2 time points above 22.5 nmol/L
b Non-supplemented: defined as women who had not taken folic acid supplements based on serum folate 
concentrations on 2 time points below 22.5 nmol/L.
c Concentrations of biomarkers in follicular fluid are given in concentration per g total protein.
d Embryo scores ranged from 1 (best quality) to 5 (poor quality and inadequate for embryo transfer).
e Mixed model analysis with 2log transformed biomarker concentrations with the potential confounders 
1age included in the model ( P ≤ 0.1).
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Table 4. Associations between the levels of the biomarkers of the homocysteine pathway in 
monofollicular fluid and the chance of achieving pregnancy in women with single embryo transfer (n = 
58).
 Median a (range) Adjusted Odds 
Ratio 95% CI
 P-value
Folate (nmol/g) 0.57 (0.12-4.04) 3.26 1.09, 9.71 0.03
Cobalamin (pmol/g) 3.84 (1.80-81.29) 1.21 0.69, 2.11 0.51
tHcy (μmol/g) 0.12 (0.07-0.80) 0.37 0.07, 1.95 0.24
Logistic regression analyses with 2logtransformed concentrations of the biomarkers. The Odds Ratio’s are 
adjusted for the potential confounder age ( P ≤ 0.1). a Concentrations of biomarkers in monofollicular fluid 
are given in concentration per g total protein.
CI, confidence interval.
DisCussion
In this study, we have demonstrated that folate, cobalamin and tHcy levels in monofollicu-
lar fluid are related to embryo quality and the chance of achieving biochemical pregnancy 
in women undergoing IVF/ICSI.
These associations are of particular importance with regard to folic acid campaigns 
and food fortification programs. It is the Dutch policy to advise all women who want to 
become pregnant to take a folic acid supplement of 0.4 - 0.5 mg/day. Data from the ques-
tionnaire indicated that about 86 % of the subfertile patients took a folic acid containing 
supplement prior to and during IVF treatment. However, after verification of the intake 
by the biomarker concentration of folate in blood, thereby using the cut-of value of 22.5 
nmol/L as defined by Brouwer et al (22), it revealed that 67% of the study population had 
consistently taken folic acid. Although the use of folic acid in our study population is much 
higher compared to that reported in Dutch pregnant women (28), it was surprisingly 
low for a highly motivated, informed group of subfertile patients participating in a study 
directed on nutrition and lifestyle. On the other hand, 24% of the supplemented women 
reported taking more than one folic acid containing supplement, resulting in very high 
folate concentrations in blood and follicular fluid. Therefore, even in highly motivated, 
subfertile patients more education about folic acid supplementation seems necessary.
Of most interest is the significant correlation between monofollicular fluid folate and 
the occurrence of biochemical pregnancy. The importance of folate as a determinant of 
embryo quality is illustrated by the correlation between monofollicular fluid cobalamin 
and embryo quality observed in non-supplemented women. The harmful effect of a rela-
tive shortage of cobalamin in monofollicular fluid could only be demonstrated when the 
folate concentrations were also relatively low. Folate is a methyl group donor in the homo-
cysteine pathway but also for many other pathways involving protein synthesis. Therefore, 
a shortage of several folate dependent proteins is suggested to play a significant role in 
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the periconception period (29). Folate deficiency can also lead to mutations caused by the 
incorporation of uracil into the DNA instead of thymine (30, 31). Repair processes which 
remove the misincorporated uracil often fail, leading to double strand breaks and chromo-
some instability which promotes apoptosis (30, 31). Synthesis and repair of DNA as well as 
methylation of DNA is crucial in gametogenesis, fertilization and pregnancy (32, 33). The 
majority of the women had normal to high folate concentrations. However, the optimal 
folate concentration in monofollicular fluid to increase the chance of pregnancy still has 
to be determined.
In the total group of women and the subgroup of non-supplemented women the mean 
blood cobalamin concentration was positively correlated with mean embryo quality. In 
the subgroup of women who had not taken folic acid supplements, cobalamin in mono-
follicular fluid was also associated with a better quality of the corresponding embryo. 
Cobalamin is a cofactor for the folate-dependent methionine synthase, which is involved 
in homocysteine remethylation. A low cobalamin concentration reduces methionine syn-
thase activity, lowering the concentration of methionine. Methionine is either incorporated 
in various peptides or transmethylated into S-adenosylmethionine (SAM). A deficiency 
of SAM reduces DNA methylation and consequently leads to hypomethylation of DNA 
which may lead to aberrant patterns of gene expression (34). Another consequence of low 
cobalamin concentrations is a decreased bioavailability of folate and a decreased activity 
of the mitochondrial methylmalonyl CoA mutase. Several small studies and case reports 
have reported an association between cobalamin deficiency and female subfertility (14, 
17, 18) but the mechanisms behind this association are not clear. In the present study 
serum cobalamin concentrations were correlated with embryo quality but not with preg-
nancy. The latter observation may be explained by the power of the study. Thus, women 
without clinical symptoms of cobalamin deficiency, but with a marginal cobalamin state 
may benefit from additional cobalamin supplementation.
Interestingly, the association between monofollicular fluid tHcy concentrations and 
embryo quality differed between the subgroups of supplemented and non-supplemented 
women. In non-supplemented women the monofollicular tHcy concentrations were 
slightly but statistically significantly higher compared to supplemented women (0.14 
versus 0.12 μmol/g protein). In these women tHcy was negatively correlated with embryo 
quality. This is in line with our previous findings (11). However, in supplemented women 
tHcy in monofollicular fluid was positively correlated with embryo quality. These data may 
suggest that there must be an optimal monofollicular tHcy concentration. The detrimental 
effect of high tHcy concentrations might be due to an excessive production of reactive 
oxygen species (ROS) thereby inducing excessive oxidative stress. However, physiological 
levels of ROS in follicular fluid are necessary for oocyte maturation (35), ovulation (36) and 
fertilization and therefore a very low tHcy concentration may be detrimental as well.
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Correlations between tHcy, folate and embryo quality and pregnancy were only 
statistically significant in monofollicular fluid. Biomarker concentrations in blood and 
monofollicular fluid are significantly correlated but the levels are not similar (19). In order 
to demonstrate also significant correlations between biomarkers in blood and outcome 
parameters, it may be necessary to extend the sample size.
The limitations of this study have to be considered as well. The included patients are 
a sample of women undergoing IVF with or without ICSI in our clinic. They constitute a 
heterogeneous group in terms of race, age and indication of treatment. However, they 
are representative for this particular population. The participation in this study may have 
influenced lifestyle behaviors, which may explain the relatively high number of folic acid 
supplement users compared to the 43 % in the general Dutch population (28). To define 
folic acid users the cut-off value of women in reproductive age, i.e., 22.5 nmol/L, is used 
(22). The age range of our population was between 24 and 44 years and was only slightly 
older than those described by Brouwer et al. (aged 18-40 years). It is not very likely that 
these women react differently on folic acid supplementation. However, this cannot be 
excluded. Furthermore, there are no other cut off points available from populations more 
similar to ours. The strength of our study is the large sample size and the biomarkers 
determined in both blood and most importantly in monofollicular fluid. Although ongo-
ing pregnancy and pregnancy outcome would have been interesting endpoints to study, 
for these associations the present study was underpowered.
In conclusion, we have shown that high concentrations of folate in monofollicular fluid 
are associated with an increased chance of achieving biochemical pregnancy. Cobalamin 
concentrations in early follicular phase serum and in monofollicular fluid are positively 
correlated with embryo quality, whereas both low and high concentrations of tHcy in 
monofollicular fluid are associated with reduced embryo quality, suggesting that there 
must be an optimal level. These findings support the importance of periconception folic 
acid supplementation and may suggest the additional intake of cobalamin. Clearly, further 
studies are now required to confirm these data and to find the best and safest B vitamin 
dosages.
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PART II
The homocysteine pathway and 
male fertility

Chapter 6
Seminal plasma cobalamin 
significantly correlates with 
sperm concentration in 
males undergoing IVF or ICSI 
procedures.
Jolanda C. Boxmeer, Marij Smit, Robertus F. Weber, Jan 
Lindemans, Johannes C. Romijn, Marinus J. Eijkemans, Nick S. 
Macklon, Régine P.M. Steegers-Theunissen
J Androl. 2007;28(4):521-7
C
ha
p
te
r 6
76
aBsTraCT:
A mild hyperhomocysteinemia is caused by B-vitamin deficiencies. We hypothesize that 
these biochemical derangements detrimentally affect spermatogenesis. Therefore, the 
aim of this study was to investigate the folate, cobalamin, pyridoxine and homocysteine 
concentrations in blood and seminal plasma and the associations between these 
biomarkers and semen parameters in males participating in an in vitro fertilization or 
intracytoplasmic sperm injection program. From 73 men (median age [range]: 37 [28-53] 
years) a blood and semen sample were obtained for the determination of serum and 
red blood cell (RBC) folate, serum total cobalamin, whole-blood pyridoxal‘5-phosphate, 
plasma total homocysteine (tHcy) and serum total testosterone. Semen analysis included 
sperm concentration, motility and morphology according to World Health Organization 
criteria. The B-vitamins and tHcy concentrations were significantly correlated in blood 
but not in seminal plasma. The serum and RBC folate concentrations were significantly 
correlated also with the total folate concentration in seminal plasma (r = 0.44; P < 0.001 
and r = 0.39; P < 0.001, respectively). Likewise, the total cobalamin concentration in serum 
and seminal plasma was significantly correlated (r = 0.55; P = 0.001). Of interest is that 
the total cobalamin concentration in seminal plasma was significantly correlated with the 
sperm concentration (r = 0.42; P < 0.001). This is in contrast to the absence of significant 
associations between the other vitamins and tHcy in blood and seminal plasma and any of 
the semen parameters. These findings suggest that folate and cobalamin are transferred 
from the blood to the male reproductive organs and emphasize the role of cobalamin in 
spermatogenesis in human.
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inTroDuCTion
Spermatogenesis is influenced by a combination of endocrine, genetic and environmental 
factors, including nutrition and lifestyle (1, 2). Evidence is increasing that nutritional factors 
are important in reproduction and thus in spermatogenesis as well. Of main interest are 
the B-vitamins folate, cobalamin and pyridoxine involved in homocysteine metabolism.
Folate is essential as a substrate in the synthesis of DNA and RNA precursors and in 
the remethylation of homocysteine into methionine. In folate-dependent homocysteine 
remethylation, vitamin B12 (cobalamin) is a cofactor for the methionine synthase enzyme. 
Vitamin B6 (pyridoxal’5-phosphate [PLP]), however, is as a cofactor for cystathionine-β-
synthase, which is necessary for the transsulphuration of homocysteine into cystathionine 
and cysteine. A deficiency of these vitamins causes a mild hyperhomocysteinemia in 
blood plasma, which is associated with several health problems, including cardiovascular 
and cerebrovascular diseases (3). Furthermore, hyperhomocysteinemia has been associ-
ated with reproductive disorders, such as recurrent pregnancy loss, abruptio placentae 
and congenital malformations (4, 5). Folic acid treatment significantly reduces the plasma 
total homocysteine (tHcy) concentrations (3). The beneficial effects of folic acid supple-
mentation in the reduction of congenital malformations can partly be explained by the 
correction of the hyperhomocysteinemia (3). We recently showed a significant inverse 
association between embryo quality following in vitro fertilization (IVF)/ intracytoplasmic 
sperm injection (ICSI) treatment and the tHcy concentration in seminal plasma and ovar-
ian follicular fluid (6).
Total seminal plasma folate concentrations are significantly correlated with blood plasma 
folate concentrations (7). Moreover, folate derivatives other than 5-methyltetrahydrofolate 
in seminal plasma appear to be correlated with sperm count (7). Further evidence for the 
role of synthetic folic acid in spermatogenesis is derived from our randomized controlled 
trial demonstrating a 74% increase in sperm count after folic acid and zinc sulphate inter-
vention for 26 weeks (8).
The effect of cobalamin in reproduction is less defined, although there is some evi-
dence that this B-vitamin affects sperm parameters (9, 10). During the sixties and seven-
ties several studies described the successful treatment of subfertility in men and women 
following treatment of a cobalamin deficiency (11-15). There is no information about the 
effects of pyridoxine on human reproduction. From animal studies it is known that high 
doses of pyridoxine impair sperm motility and sperm count and cause histopathological 
changes including degeneration of germinal epithelial cells (16).
From this background, we investigated the total folate, total cobalamin, pyridoxine as 
pyridoxal-5’-phosphate and tHcy concentrations in blood and seminal plasma in males, 
and the association with semen parameters.
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meThoDs
Study Subjects
As part of an ongoing prospective study focused on the role of nutrition, in particular 
folate, in fertilization, implantation and embryo quality (FOLFO-Study), we enrolled 
couples undergoing an IVF or ICSI procedure at the Erasmus MC, University Medical Center 
in the Netherlands. Fertile and subfertile males were eligible for enrolment unless frozen 
or surgically retrieved sperm was to be used for the assisted reproductive treatment. Fertil-
ity is defined by a sperm concentration of more than 20 x 106 cells/mL. Of the eligible IVF/
ICSI population 66% of the males participated in the FOLFO-Study resulting in the analysis 
of the data of 73 males. The study protocol was approved by the Central Committee for 
Human Research (CCMO) in The Hague, The Netherlands and the Medical Ethical and 
Institutional Review Board of the Erasmus MC, University Medical Center in Rotterdam, 
The Netherlands. All participants gave their written informed consent.
Study protocol
At the intake visit the IVF treatment couples were asked to participate in the study. 
Between 2 weeks before and 2 weeks after oocyte retrieval men visited the andrology 
outpatient clinic for fertility evaluation comprising semen analysis, blood withdrawal, and 
scrotal ultrasound. One semen sample and blood sample were collected from each man. 
All laboratory analyses were performed without knowledge of the clinical diagnosis of 
the participants. The ultrasonic volume of each testis was calculated from 3 perpendicular 
measurements in the equation V (mL) = π x length x width x depth (all in cm)/6. The mean 
testicular volume was calculated for each participant.
Semen samples were produced via masturbation into polypropylene containers. After 
liquefaction, semen analysis according to the World Health Organization (WHO) guidelines 
were performed (17). Subsequently an aliquot of semen was centrifuged at 2,500 x g for 
10 minutes. The supernatant seminal plasma was frozen without preservatives and stored 
at –20°C until assayed.
Venous blood samples were drawn into dry vacutainer tubes and allowed to clot. After 
centrifugation at 2,000 x g, the blood serum was collected before being assayed for the 
concentrations of total folate, total cobalamin and testosterone. For the determination 
of red blood cell (RBC) folate and plasma tHcy, venous blood samples were drawn into 
ethylenediamine tetra-acetate (EDTA)-containing vacutainer tubes. The EDTA-blood 
samples were kept on ice, and plasma was separated by centrifugation within 1 hour for 
determination of tHcy. For the determination of pyridoxine, blood was drawn into lithium-
heparin-containing vacutainers.
Blood serum and seminal plasma samples from each patient were analyzed dur-
ing routine laboratory procedures for total folate and total cobalamin using an 
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immunoelectrochemoluminescence assay (Roche Modular E170, Roche Diagnostics 
GmbH, Mannheim, Germany). Directly after blood sampling, 0.1 mL blood out of an EDTA 
tube was hemolyzed with 0.9 mL freshly prepared 1.0% ascorbic acid. Subsequently the 
hematocrit of the EDTA-blood was determined on an ADVIA 120 Hematology Analyzer 
(Bayer Diagnostics, Germany). The hemolysate was centrifuged for five minutes at 1,000 
x g shortly before the folate measurement. The folate concentration in the hemolysate 
was recalculated in RBC folate using the following formula: (nM hemolysate folate x 10 / 
hematocrit) - (nM serum folate x [1- hematocrit] / hematocrit) = nM RBC folate. Pyridox-
ine in whole blood and seminal plasma and tHcy in EDTA plasma and seminal plasma 
were determined during routine laboratory procedures using high-performance liquid 
chromatography with reversed-phase separation and fluorescence detection (18, 19). We 
determined total pyridoxine with PLP being the most common form. Testosterone was 
measured using Coat-a-Count radioimmunoassay (Diagnostic Products Corp., Los Ange-
les, CA).
The between-run coefficient of variation for serum total cobalamin was 5.1% at 125 
pmol/L and 2.9% at 753 pmol/L; for serum total folate these coefficients of variation were 
9.5% at 8.3 nmol/L and 3.2% at 20.2 nmol/L, for tHcy 3.3% at 14.55 µmol/L and 2.3% at 
34.23 µmol/L, for pyridoxine these coefficients of variation were 1.8% at 40 nmol/L and 
1.3% at 115 nmol/L, for testosterone these coefficients of variation were less than 7.5%. 
The detection limit for total folate was 1.36 nmol/L, for total cobalamin 22 pmol/L, for 
pyridoxine 5 nmol/L and for tHcy 4 µmol/L, for testosterone 0.1 nmol/L. In addition, males 
filled out a general questionnaire from which the following data were extracted: medical 
history, education, use of medication, and lifestyle factors, such as smoking and the use of 
vitamin supplements.
Statistical Analysis
The results were expressed as median (range) or as a percentage and analyzed for sta-
tistical significance using nonparametric tests, because of a skewed distribution of the 
semen parameters and B-vitamins and tHcy in blood and seminal plasma. Spearman rank 
correlation coefficients were calculated to determine associations between semen param-
eters and total folate, total cobalamin, PLP and tHcy concentrations in blood and seminal 
plasma. In the figures we present the log transformed variables.
To adjust for possible confounding variables, a multiple linear regression analysis was 
performed with the logarithm of semen concentration as dependent variable. In this 
analysis, age, body mass index (BMI), smoking, alcohol, medication, intake of multivitamin 
supplements, intake of folic acid supplements, serum total testosterone, mean testicular 
volume measured by ultrasound, a history of urologic surgery, and the presence of a 
varicocèle were considered as potential confounding factors.
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resuLTs
The population characteristics and semen parameters are presented in Table 1. Due to a 
low semen volume, concentrations of total folate and total cobalamin could not be deter-
mined in 2 samples, and PLP and tHcy concentrations were missing in 7 and 19 semen 
samples, respectively. The median serum testosterone was 14.5 nmol/L (range: 5.8 – 31.9). 
The median of the mean testicular volume was 10.9 mL (range: 5.5 – 22.0). In the study 
population a varicocele was diagnosed in 17 participants (26%) and 5 men (7%) had a 
history of urologic surgery. Twelve men used medication for the following categories of 
diseases [n]: cardiovascular [3], enterologic [3], psychologic [2], respiratory [2], metabolic 
[1] and dermatologic [1]. None of these drugs are known to affect sperm parameters or 
the concentrations of B-vitamins and tHcy. According to the sperm concentration in the 
semen sample for this study 34% of the participants were subfertile (≤ 20 x 106 cells/mL)
Table 1. Characteristics and semen parameters of 73 males in an IVF/ICSI program
Characteristics
Age median, years (range) 37 (28-53)
Body mass index median (range) 22.3 (17.7 – 28.9)
Smoking – yes, % (n) 25 (16)
Medication – yes, % (n) 19 (12)
Folic acid supplement - yes, % (n) 8 (5)
Multivitamin supplement - yes, % (n) 37 (23)
Educational level Low, % (n)
 Intermediate, % (n)
 High, % (n)
14 (9)
41 (26)
44 (28)
Cause of subfertility: Male facto,r % (n)
 Female factor, % (n)
 Male and female factor, % (n)
 Idiopathic, % (n)
26 (19)
23 (17)
1 (1)
49 (36)
Sperm concentration (x 106 cells/mL),* median (range) 30 (1.6-278)
Sperm progressive motility (%),* median (range) 35 (8-65)
Normal sperm morphology (%),* median (range) 5 (0-15)
*Determination according to World Health Organization criteria (1999). Normal reference values are > 20 x 
106 cells/mL sperm concentration, >50% motility, and ≥ 30% normal morphology. The cause of subfertility 
is based on the medical history and previous examinations of the couples.
Table 2. Concentrations of B vitamins and tHcy in blood and seminal plasma
Vitamins Blood median (range) Seminal plasma median (range)
Total Folate serum (nmol/L) 14.7 (8.9-131.1) 25.7 (13.8-78.6)
Folate RBC (nmol/L) 973.5 (558-2195)
Total Cobalamin (pmol/L) 317 (141-696) 509 (94-1260)
Pyridoxal’5-phosphate (nmol/L) 76 (40-300) 24 (0-300)
tHcy (μmol/L) 11.6 (7-28.7) 6.8 (1.7-35.5)
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The total folate and total cobalamin concentrations in serum were significantly lower 
than in seminal plasma (P < 0.001 and P < 0.001), and RBC folate and pyridoxine concentra-
tions were significantly higher (P < 0.001 and P < 0.001) in blood than in seminal plasma. 
The tHcy concentrations in serum and seminal plasma were comparable (P = 0.137) 
(Table 2). In blood, the total folate, total cobalamin, PLP and tHcy concentrations were 
significantly correlated with each other, but in seminal plasma no significant correlations 
between these B-vitamins and tHcy could be determined. In addition, significant correla-
tions were determined between serum, RBC and seminal plasma total folate as well as 
between serum and seminal plasma total cobalamin (Figure 1). No significant correlations 
were observed between the tHcy and PLP concentrations in blood and seminal plasma.
A significant correlation was determined between cobalamin in seminal plasma and 
sperm concentration (r = 0.42; P ≤ 0.001) (Figure 2). The other B-vitamins and tHcy in blood 
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1. Folate in serum and seminal plasma: 
r = 0.44 (P < 0.001)
2. Folate in red blood cells (RBC) and in seminal plasma: 
r = 0.39 (P = 0.001)
3. Cobalamin in serum and in seminal plasma: 
r = 0.55 (P < 0.001)
4. Pyridoxal’5-phosphate in whole blood and in seminal plasma:
r = 0.14 (P = 0.26)
5. tHcy in plasma and in seminal plasma: 
r =-0.12 (P = 0.41)
Figure 1. Logtransformed B-vitamin and tHcy concentrations in blood and seminal plasma.
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and seminal plasma were not significantly correlated with any of the semen parameters. 
We adjusted this significant correlation for possible confounders by multiple linear regres-
sion analysis with the logarithm of the semen concentration as dependent variable and the 
concentration of cobalamin in seminal plasma as independent variable. None of the fac-
tors considered as potential confounders (age, BMI, smoking, alcohol, medication, intake 
of multivitamin supplements, intake of folic acid supplements, serum total testosterone, 
mean testicular volume measured by ultrasound, a history of urologic surgery, and the 
presence of a varicocèle) reached statistical significance. In this linear regression model 
the corresponding standardized regression coefficient was 0.35 (P = 0.012). After correc-
tion for the previously described variables, the regression coefficient was only marginally 
different compared to the crude estimate (r = 0.34; P = 0.013).
DisCussion
In this study, we clearly demonstrate a significant positive correlation between the total 
cobalamin concentration in seminal plasma and the sperm concentration in men partici-
pating in an IVF or ICSI procedure. Moreover, the total cobalamin concentration in serum 
was significantly correlated with the seminal plasma concentration.
Tomaszewski et al. (1963) found lower cobalamin concentrations in males with oli-
gospermia than in males with a normal semen concentration, which is in line with our find-
ing (10). It was previously suggested that cobalamin influences the maturation of human 
spermatozoa (9). Our data, however, are not showing a significant correlation between 
sperm morphology and cobalamin concentrations. Differences in the distributions of the 
Figure 2. Correlation between logtransformed cobalamin concentrations in seminal plasma and 
logtransformed sperm concentration.
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sperm morphology in both studies and the method of determining sperm morphology 
may explain these differences.
According to the criteria of the WHO, all males participating in the present study 
should be classified as subfertile, because of their low sperm morphology scores (17). The 
threshold for sperm morphology, however, is widely debated and several authors have 
advocated a lower threshold (20, 21). For that reason, we defined male subfertility in our 
study by the sperm concentration of less than 20 x 106 cells/mL.
Of interest is that in the 1960s and 1970s subfertile, cobalamin-deficient men were 
described who became fertile after treatment with cobalamin (11, 14). In our study, how-
ever, only 1 man showed a borderline cobalamin concentration (141 pmol/L; normal: > 
145 pmol/L) with a normal semen analysis (118 x 106 cells/mL, 43% progressive motility, 
7% normal sperm morphology). Although the sperm morphology was below the WHO 
criteria, there is still a lot of discussion about the definition of ‘normal’ sperm morphology 
(17, 21).
Another interesting finding is the significant correlation between the total folate 
concentration in blood and seminal plasma. The total folate concentrations in serum and 
seminal plasma were slightly lower and in RBC slightly higher than the pre-intervention 
concentrations in fertile and subfertile males reported by us previously (8). This might be 
due to laboratory differences, such as the use of different assays, population differences 
and changes in dietary patterns and life styles in the last decade in the Netherlands. This 
is also in line with the slightly higher tHcy concentrations in seminal plasma compared to 
the concentrations reported by Ebisch et al (6).
A significant correlation between the total folate concentration in seminal plasma and 
sperm parameters could not be determined. This is in contrast to the results of Wallock 
et al, which demonstrated a significant correlation between the nonmethylated folate 
derivatives, in particular, and sperm count (7). This difference may be due to the fact that 
they determined a subgroup of nonmethylated folate derivatives while we measured 
mainly methyltetrahydrofolate.
The absence of a correlation between tHcy and sperm parameters is consistent with 
the results from Ebisch et al (6). However, in that study we assessed a significant asso-
ciation between the embryo quality and the tHcy concentration in both seminal plasma 
and follicular fluid. This emphasizes the importance of considering both male and female 
parameters in the investigation of (sub) fertility.
In general, the correlations between total cobalamin, total folate and PLP in blood are 
rather small, which is very likely due to the many factors that determine these biomark-
ers, such as diet, medication, supplement use, metabolism, and genetic variations. The 
significant correlations between tHcy and total folate and total cobalamin are well known 
(3). The absence of significant correlations between total folate, total cobalamin and PLP in 
seminal plasma, however, are new.
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The rationale for the determination of seminal plasma concentrations of the B-vitamins 
and tHcy was to gain more insight into tissue-specific concentrations and the associations 
with sperm parameters. The correlations between blood and seminal plasma for total 
folate and total cobalamin suggest a transfer of these nutrients between the 2 compart-
ments. On the other hand, seminal plasma is not only derived from the testis but also from 
the epididymis and prostate. Therefore, the best but not very popular manner to get more 
information into the role of these nutrients in human spermatogenesis is to determine 
these concentrations in local samples obtained by a testicular biopsy.
Some limitations of the present study have to be addressed. The study has been per-
formed in a population of subfertile couples and in 27% of the couples a male factor was 
present. It would be interesting to repeat our study in extended groups of both fertile 
and subfertile men. For the group of fertile males, couples with female factor fertility can 
be considered but males with healthy children after spontaneous pregnancies would be 
even better. Moreover, considering normal physiology we expect that the associations are 
independent of the fertility status of the males.
Furthermore, the finding of a correlation between total cobalamin in seminal plasma 
and sperm concentration does not equate to causality. More research on this subject 
should be performed to clarify the role of cobalamin in spermatogenesis.
In summary, the strong correlation between seminal plasma total cobalamin and sperm 
concentration supports the role of this vitamin, besides that of folate, in spermatogenesis 
in human. Because male factor subfertility due to cobalamin deficiency is amendable to 
curative and/or preventive action by supplementation, studies should focus on the deter-
mination of cut off points of cobalamin concentration in blood and seminal plasma and 
the efficacy and safety of supplementation on semen parameters and fertility as outcome 
measures.
Acknowledgements
The authors gratefully acknowledge the contribution of the IVF team of the Division of 
Reproductive Medicine, and the laboratory technicians and research assistants of the 
Department of Andrology and Laboratory of Clinical Chemistry of the Erasmus MC, Uni-
versity Medical Center in Rotterdam, The Netherlands for the collection and laboratory 
determinations.
Homocysteine biomarkers and sperm quality (I) 85
reFerenCes
 1. Kuroki Y, Iwamoto T, Lee JW, Yoshiike M, Nozawa S, Nishida T, et al. Spermatogenic ability is different 
among males in different Y chromosome lineage. J Hum Genet 1999; 44(5): 289-92.
 2. Wong WY, Thomas CM, Merkus JM, Zielhuis GA, Steegers-Theunissen RP. Male factor subfertility: pos-
sible causes and the impact of nutritional factors. Fertil Steril 2000; 73(3): 435-42.
 3. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations 
about total homocysteine determinations: An expert opinion. Clin Chem 2004; 50(1): 3-32.
 4. Steegers-Theunissen RP, Boers GH, Trijbels FJ, Eskes TK. Neural-tube defects and derangement of 
homocysteine metabolism. N Engl J Med 1991; 324(3): 199-200.
 5. Steegers-Theunissen RP, Boers GH, Blom HJ, Trijbels FJ, Eskes TK. Hyperhomocysteinaemia and recur-
rent spontaneous abortion or abruptio placentae. Lancet 1992; 339(8801): 1122-3.
 6. Ebisch IM, Peters WH, Thomas CM, Wetzels AM, Peer PG, Steegers-Theunissen RP. Homocysteine, 
glutathione and related thiols affect fertility parameters in the (sub)fertile couple. Hum Reprod 2006; 
21(7): 1725-33.
 7. Wallock LM, Tamura T, Mayr CA, Johnston KE, Ames BN, Jacob RA. Low seminal plasma folate concen-
trations are associated with low sperm density and count in male smokers and nonsmokers. Fertil 
Steril 2001; 75(2): 252-9.
 8. Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP. Effects of folic 
acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. 
Fertil Steril 2002; 77(3): 491-8.
 9. Watson AA. Seminal vitamin B12 and sterility. Lancet 1962; 280(7257): 644-.
 10. Tomaszewski L, Zmudzka B, Nadworny J. Seminal vitamin B12 and sterility. Lancet 1963; 281(7273): 
170.
 11. Sharp AA, Witts LJ. Seminal vitamin B 12 and sterility. Lancet 1962; 280(7259): 779.
 12. Jackson I, Doig WB, McDonald G. Pernicious anaemia as a cause of infertility. Lancet 1967; 290(7527): 
1159-60.
 13. Varadi S. Pernicious anaemia and infertility. Lancet 1967; 290(7529): 1350.
 14. Blair JH, Stearns HE, Simpson GM. Vitamin B 12 and fertility. Lancet 1968; 1(7532): 49-50.
 15. Mahmood A. Pernicious anaemia as a cause of infertility. Lancet 1971; 297(7702): 753.
 16. Plassmann S, Urwyler H. Improved risk assessment by screening sperm parameters. Toxicology Let-
ters 2001; 119(2): 157-71.
 17. World Health Organization. (1999) Laboratory Manual for the examination of human semen and 
semen-cervical mucus interaction. 4th ed, Cambridge University Press, Cambridge.
 18. Schrijver J, Speek AJ, Schreurs WH. Semi-automated fluorometric determination of pyridoxal-5’-
phosphate (vitamin B6) in whole blood by high-performance liquid chromatography (HPLC). Int J 
Vitam Nutr Res 1981; 51(3): 216-22.
 19. Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay for plasma total homocysteine and 
cysteine in a clinical laboratory setting. Clin Chem 1999; 45(2): 290-2.
 20. Ombelet W, Bosmans E, Janssen M, Cox A, Vlasselaer J, Gyselaers W, et al. Semen parameters in a fertile 
versus subfertile population: A need for change in the interpretation of semen testing. Hum Reprod 
1997; 12(5): 987-93.
 21. van der Merwe FH, Kruger TF, Oehninger SC, Lombard CJ. The use of semen parameters to identify the 
subfertile male in the general population. Gynecol Obstet Invest 2005; 59(2): 86-91.

Chapter 7
Low folate in seminal plasma is 
associated with increased sperm 
DNA damage
Jolanda C. Boxmeer, Marij Smit, Elaine Utomo, Johannes C. 
Romijn, Marinus J.C. Eijkemans, Jan Lindemans, Joop S.E. Laven, 
Nick S. Macklon, , Eric A.P. Steegers, Régine P.M. Steegers-
Theunissen.
Fertil Steril. 2008 Aug 21 [Epub ahead of print]
C
ha
p
te
r 7
88
aBsTraCT
objective: To determine associations between B vitamin status, homocysteine (tHcy), 
semen parameters and sperm DNA damage.
Design: Observational study.
setting: A tertiary referral fertility clinic.
Patients: Two hundred fifty-one men of couples undergoing in vitro fertilization (IVF) or 
intracytoplasmic sperm injection (ICSI) treatment. Subgroups of fertile (n = 70) and subfer-
tile men (n = 63) were defined according to semen concentration and proven fertility.
interventions: None.
main outcome measure(s): The DNA fragmentation index (DFI) as marker of sperm 
DNA damage was determined using the Sperm Chromatin Structure Assay (SCSA), and 
semen parameters were assessed according to World Health Organization criteria. In 
seminal plasma and blood, tHcy, folate, cobalamin and pyridoxine concentrations were 
determined.
results: In the total group of fertile and subfertile men, all biomarkers in blood were 
significantly correlated with those in seminal plasma. No correlation was found between 
the biomarkers in blood and the semen parameters. In seminal plasma, both tHcy and 
cobalamin positively correlated with sperm count. Folate, cobalamin, and pyridoxine were 
inversely correlated with ejaculate volume. In fertile men, seminal plasma folate showed 
an inverse correlation with the DNA fragmentation index.
Conclusions: Low concentrations of folate in seminal plasma may be detrimental for 
sperm DNA stability.
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inTroDuCTion
In general, male subfertility is of multifactorial origin. Whereas genetic causes of subfer-
tility are difficult to modulate, other conditions such as accessory gland infections and 
vas deferens obstruction are potentially treatable. Environmental and lifestyle factors are 
also potentially amenable and thereby may cure or prevent the subfertility. Nutrition is 
an important modifier, but one that is largely ignored in the counseling and treatment of 
these patients. In recent years, interest has increased in the role of B-vitamins as modula-
tors of fertility outcome (1, 2). Deficient B vitamin concentrations cause elevated homo-
cysteine concentrations and impair the remethylation cycle. This metabolism is involved 
in the methylation of phospholipids, proteins, DNA, and RNA, and in the synthesis and 
repair of DNA. These processes are essential in spermatogenesis; therefore, derangements 
in this pathway may be detrimental for reproduction. Recently, our group demonstrated 
an adverse effect of a high total homocysteine (tHcy) concentration in ejaculated sperm 
and follicular fluid on embryo quality (3). Moreover, we showed in a randomized, placebo-
controlled trial that during 6 months of intervention with folic acid and zinc phosphate 
a 74% increase of total normal sperm count in subfertile men could be achieved (4). The 
effect of cobalamin in reproduction is less defined, although there is some evidence that 
this B vitamin affects sperm parameters as well (5-8).
Conventional semen analysis consists of measuring a variety of semen parameters 
including volume, sperm concentration, motility, and morphology. Nowadays, the DNA 
fragmentation index (DFI) can be assessed by the Sperm Chromatin Structure Assay 
(SCSA), an independent measure of sperm quality with a better diagnostic and prognostic 
capability than the conventional semen analysis alone (9, 10). During spermatogenesis, 
most of the cytoplasm of the spermatozoa is discarded, through which the availability of 
nutrients and defensive cytosolic enzymes is limited. This may result in a higher sensitivity 
for DNA damage. During ejaculation, the microenvironment of the spermatozoa is formed 
by the seminal plasma. It contains a broad spectrum of nutrients, enzymes, and hormones 
necessary to maintain normal metabolism and function of the spermatozoa. Deficiencies 
or excessive concentrations may be detrimental to the spermatozoa. So far, the effects 
of seminal plasma tHcy and B vitamins on semen parameters have scarcely been stud-
ied. Our study investigated the associations between 1) B vitamin and homocysteine 
concentrations in blood and seminal plasma, 2) the biomarkers and conventional semen 
parameters, and 3) the biomarkers and sperm DNA damage.
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Study Population
Between September 2004 and January 2007, subfertile couples undergoing in vitro 
fertilization (IVF) with or without intracytoplasmic sperm injection (ICSI) treatment at the 
Erasmus MC, University Medical Center in Rotterdam, the Netherlands were included in 
the prospective FOod, Lifestyle and Fertility Outcome-study (FOLFO-study). The FOLFO 
project was set up to study the influence of preconception nutrition and lifestyle on fertil-
ity and pregnancy outcome. In the present analysis, the male participants are evaluated. 
Fertile and subfertile men were eligible for enrollment unless semen was cryopreserved or 
obtained by microsurgical or percutaneous epididymal sperm aspiration (MESA or PESA). 
Couples were invited to participate in the study at the intake visit. The study protocol was 
approved by the Dutch Central Committee for Human Research in and the Medical Ethical 
and Institutional Review Board of Erasmus MC, University Medical Center in Rotterdam, 
the Netherlands. All participants gave their written informed consent.
For the standard fertility evaluation, men visited the andrology outpatient clinic. The 
fertility evaluation comprised semen analysis, blood sampling, a physical examination 
including a scrotal ultrasound, and a general questionnaire. All obtained materials were 
processed anonymously. During physical examination scrotal ultrasonography was 
performed using a Toshiba Nemio 20 with a 12-Hz transducer (Toshiba, Tokyo, Japan). A 
varicocele was diagnosed when at least two venous vessels with a diameter of at least 3 
mm were present, in addition to reflux or diameter increase during Valsalva’s maneuver.
Furthermore, all participants filled out a general questionnaire from which the follow-
ing data are extracted: medical history, body height and weight, ethnicity, and lifestyle 
factors such as the use of alcohol, cigarettes, and vitamin supplements.
To stratify the participants in subgroups of fertile and subfertile men, fertile men were 
defined by a sperm concentration of ≥20x106 cells/mL and a prior conception with the 
current or previous partner. Subfertile men were defined by a sperm concentration of 
<20x106 cells/mL and no prior conception.
Semen Collection and Analysis
Semen specimens were produced via masturbation after a required abstinence period of 
3 to 5 days. After liquefaction, the semen parameters of volume, sperm concentration, 
sperm count, percentage progressive motility, and percentage normal morphology were 
assessed according to the WHO guidelines (11). An aliquot of unprocessed semen was 
stored at -80°C to determine the DFI at a later stage. Subsequently, the remainder of semen 
was centrifuged at 2500 x g for 10 minutes. The supernatant seminal plasma was frozen 
without preservatives and stored at -20°C until assayed.
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SCSA
The principles and procedures of measuring sperm DNA damage by a FACScan flow 
cytometry SCSA have been described in detail previously (12). In short, semen samples 
were diluted with TNE buffer to a concentration of 1-2 x 106 sperm cells/mL in a volume 
of 0.20 mL. This cell suspension was mixed with 0.40 mL of acid detergent solution and 
then stained with 1.2 mL Acridine Orange (AO) staining solution. A reference sample 
treated in the same way was run prior to the actual measurements and used to adjust the 
voltage gains of the flow cytometer FL3 and FL1 photomultipliers that detected red and 
green fluorescence respectively. An aliquot of reference sample was stained and run again 
after every 5 to 10 samples. Data collection of the fluorescent pattern in 5000 cells was 
performed at 3 minutes after acid treatment. Each sperm sample was analyzed twice.
The extent of DNA damage was expressed as the DNA fragmentation index (DFI), 
reflecting the ratio for red fluorescence to total fluorescence. Cell Quest Pro and WinList 
software (Becton Dickinson, San Jose, CA, USA) were used to calculate the DFI of each 
sample.
Determination of Biomarkers in Blood and Seminal Plasma
Concentrations of tHcy, folate, cobalamin and pyridoxine were determined in venous blood 
and seminal plasma samples. In blood samples red blood cell (RBC) folate, testosterone, 
sex hormone-binding globulin (SHBG), and inhibin B were determined as well. Venous 
blood was collected in dry Vacutainer tubes (Becton Dickinson), ethylenediamine tetra-
acetate (EDTA) containing Vacutainer tubes and lithium heparin containing Vacutainers. 
After clotting, the blood collected in dry Vacutainer tubes was centrifuged at 2,000 x g and 
sera were stored at 4°C before being assayed. The venous blood samples collected in the 
EDTA containing Vacutainer tubes were kept on ice for a maximum of one hour after which 
the plasma was separated after centrifugation and stored at 4°C before being assayed. The 
venous blood that was drawn into lithium heparin containing Vacutainer was stored at 4°C 
before being assayed.
Concentrations of tHcy in EDTA plasma and seminal plasma and pyridoxine as pyridoxal 
’5-phosphate (PLP) in whole blood and seminal plasma were determined during routine 
laboratory procedures using high performance liquid chromatography with reversed 
phase separation and fluorescence detection (13, 14). For the determination of folate and 
cobalamin in blood and seminal plasma an immunoelectrochemoluminescence immuno-
assay was used (Roche Modular E170, Roche Diagnostics GmbH, Mannheim, Germany).
For the determination of RBC folate, 100 μL of blood out of one EDTA tube was hemolyzed 
with 2 mL freshly prepared ascorbic acid (0.05g ascorbic acid in 25 mL aqua dest) directly 
after blood sampling. Subsequently, the hematocrit of the EDTA-blood was determined 
on a Sysmex XE-2100 (Groffin Meyvis, Etten-Leur, The Netherlands). The hemolysate was 
centrifuged for 10 minutes at 2,000 x g shortly before the folate measurement. The folate 
C
ha
p
te
r 7
92
concentration in the hemolysate was calculated in RBC folate using the following formula: 
(nmol hemolysate folate * 21) - (nmol/L serum folate * (1- hematocrit)) / hematocrit = 
nmol/L RBC folate.
Testosterone concentrations were determined using a non-extraction coated tube 
radioimmunoassay (Coat-a-Count, Diagnostic Products Corporation, Los Angeles, USA). 
We used an immunometric technique on an Immulite Analyzer (Diagnostic Products) to 
determine SHBG, and serum inhibin B was measured by immunoenzymometric assay 
(Oxford Bio-Innovation, Kidlington, Oxford, United Kingdom).
Interassay coefficients of variation for tHcy were 4.8% at 14.6 µmol/L and 3.3% at 34.2 
µmol/L; folate 4.5% at 13 nmol/L and 5.7% at 23 nmol/L; PLP 1.8% at 40 nmol/L and 1.3 % 
at 115 nmol/L; cobalamin 3.6% at 258 pmol/L and 2.2% at 832 pmol/L; and for SHBG 6.1% 
at 11.6 nmol/L and 6.9% at 93 nmol/L. For testosterone, these coefficients of variation were 
less than 7.5%, and for inhibin B these coefficients of variation were less than 15%. The 
detection limit for tHcy was 4 µmol/L, folate 1.36 nmol/L, pyridoxine 5 nmol/L, cobalamin 
22 pmol/L, testosterone 0.1 nmol/L, SHBG 5 nmol/L and inhibin B 10 ng/L. In seminal 
plasma the lower detection limit of tHcy was defined as 3*SD = 2 µmol/L.
Statistical Analysis
Biomarker concentrations were expressed in median (range), because of the skewed dis-
tributions. Consequently these variables were log transformed prior to statistical analysis. 
Pearson correlation coefficients were calculated to determine associations between the 
biomarkers in serum and seminal plasma. Differences between fertile and subfertile men 
were tested with independent t-test or chi-square tests.
To determine associations between DFI and the semen parameters, between the bio-
markers and DFI, and semen parameters, we made a causal diagram known as directed 
acyclic graph (DAG) (15). To adjust for potential confounders, multiple linear regression 
analyses were performed. The DAG consisted of 3 blocks: one block with the biomarkers, 
one block with semen parameters (including DFI), and one block with potential confound-
ers. Age, body mass index (BMI), smoking, alcohol use, and the presence of a varicocele 
were considered as potential confounders.
The first step was to determine correlations between the variables within the block of 
biomarkers and the block of semen parameters. Secondly, the correlations between the 
two blocks were adjusted for the potential confounders and the covariates of the tested 
variables within each block. The covariates were included in the model at a significance 
level of < 0.1 in a forward stepwise regression model. The analyses were performed in the 
total group and in the two subgroups. For statistical analysis SPSS 12.0.1 was used (SPSS 
Inc., Chicago, IL,). P values ≤ 0.05 were considered statistical significant.
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resuLTs
Baseline Characteristics
The flowchart of the study is presented in Figure 1. Seventy-four percent of the eligible 
couples participated in the study. Semen samples could not be obtained from 27 men, 
and the biochemical data were missing for one individual. Thus, we evaluated the semen 
analyses and biochemical data of 251 men. According to our definition 70 men were clas-
sified as fertile and 63 as subfertile.
The baseline characteristics of the participating men and the subgroups are given in 
Table 1. Fertile men were significantly older and showed significantly higher inhibin B 
concentrations than subfertile men. Forty-one men (16 %) used one or more medicine 
for the following categories of diseases: respiratory system (10 men), gastroenterology (7 
men), endocrinology (7 men), cardiovascular (6 men), psychology (5 men), metabolic (4 
men), skin (1 man) and miscellaneous (3 men). Only few of these drugs are known to affect 
Figure 1. Flowchart of included men
Men included in the study
n = 279
n = 252
no semen
analysis
n = 27
no biochemical data
(blood + seminal plasma)
n = 1 n = 251
Subfertile men
n = 63
Intermediate
n = 118
Fertile men
n = 70
 Fertile men: sperm concentration of equal or more than 20x10
6 cells/mL and a prior conception with the 
current or previous partner. Subfertile men: a sperm concentration of less than 20x106 cells/mL and no 
prior conception.
C
ha
p
te
r 7
94
Ta
b
le
 1
. G
en
er
al
 c
ha
ra
ct
er
is
tic
s
 T
ot
al
 g
ro
up
 o
f m
en
 (n
 =
 2
51
)
N
 S
ub
fe
rt
ile
 m
en
 (n
 =
 6
3)
N
 F
er
til
e 
m
en
 (n
 =
 7
0)
N
P 
va
lu
eb
A
ge
 (y
ea
rs
)a
37
.0
(2
3.
1 
– 
59
.1
)
25
1
34
.0
(2
3.
1 
– 
46
.2
)
63
39
.1
(3
0.
5 
– 
54
.0
)
70
≤
0.
00
1
BM
I (
kg
/m
2 )
a
25
.6
(1
8.
4 
– 
38
.4
)
22
6
24
.0
(1
9.
6 
– 
37
.9
)
60
25
.8
(1
8.
8 
– 
38
.4
)
60
n.
s.
Et
ni
ci
ty
22
7
60
60
n.
s.
Eu
ro
p
ea
n 
D
ut
ch
 N
at
iv
es
18
1
(7
9.
7)
51
(8
5)
41
(6
8.
3)
Eu
ro
p
ea
n 
ot
he
rs
16
(7
.0
)
3
(5
)
5
(8
.3
)
N
on
-E
ur
op
ea
n
30
(1
3.
2)
6
(1
0)
14
(2
3.
3)
Sm
ok
in
g
22
7
60
60
n.
s.
Ye
s
57
(2
5.
1)
14
(2
3.
3)
15
(2
5)
N
o
17
0
(7
4.
9)
46
(7
6.
7)
45
(7
5)
A
lc
oh
ol
 u
se
 (u
ni
ts
/w
ee
k)
a
4.
3
(0
.0
 –
 5
0.
3)
3.
5
(0
 –
 1
7.
5)
2.
1
(0
 –
 2
7.
6)
n.
s.
Va
ric
oc
el
e
22
0
59
59
n.
s.
Ye
s
37
(1
6.
8)
12
(2
0.
3)
6
(1
0.
2)
N
o
18
3
(8
3.
2)
47
(7
9.
7)
53
(8
9.
8)
Vi
ta
m
in
 u
se
21
7
57
58
n.
s.
Ye
s,
 w
ith
 fo
lic
 a
ci
d
44
(2
0.
3)
15
(2
6.
3)
8
(1
3.
8)
Ye
s,
 w
ith
ou
t f
ol
ic
 a
ci
d
13
(6
.0
)
5
(8
.8
)
2
(3
.4
)
N
o
16
0
(7
3.
7)
37
(6
4.
9)
48
(8
2.
8)
En
do
cr
in
ol
og
ya
Te
st
os
te
ro
ne
 (n
m
ol
/L
)
15
.1
(5
.8
 –
 3
6.
0)
24
8
15
.3
(8
.8
 –
 3
4.
5)
61
14
.7
(7
.6
 –
 2
5.
2)
70
n.
s.
SH
BG
 (n
m
ol
/L
)
26
.1
(8
.1
 –
 7
0.
7)
24
8
27
.8
(1
1.
4 
– 
52
.1
)
61
25
.7
(8
.1
 –
 7
0.
7)
70
n.
s.
In
hi
b
in
 B
 (n
g/
L)
16
0.
0
(2
.0
 –
 4
11
.0
)
24
8
12
6.
0
(2
.0
 –
 3
01
.0
)
61
18
6.
5
(6
1.
0 
– 
41
1.
0)
70
≤
0.
00
1
N
ot
e:
 R
es
ul
ts
 a
re
 p
re
se
nt
ed
 a
s 
nu
m
b
er
 (%
), 
un
le
ss
 o
th
er
w
is
e 
in
di
ca
te
d
a  m
ed
ia
n 
(r
an
ge
); 
b
 d
iff
er
en
ce
 b
et
w
ee
n 
su
b
fe
rt
ile
 a
nd
 fe
rt
ile
 m
en
; i
nd
ep
en
de
nt
 T
-t
es
t o
r C
hi
-s
qu
ar
e 
(t
w
o-
ta
ile
d)
 if
 a
p
p
ro
p
ria
te
; n
.s
. =
 n
ot
 s
ig
ni
fic
an
t
Homocysteine biomarkers and sperm quality (II) 95
sperm parameters or the concentrations of B-vitamins and tHcy. Due to the small numbers 
and heterogeneity it was not possible to perform subanalysis.
Correlations between Blood and Seminal Plasma
Table 2 shows the biomarkers in blood and seminal plasma. Twelve men (5%) had hyper-
homocysteinemia (22.6 - 56.4 umol/L; reference value >22 umol/L) while only 3 men (1%) 
had a mild folate deficiency (7.1, 7.5 and 7.6 nmol/L; reference value <8 nmol/L). There 
were no significant differences between the biomarker concentrations in either blood or 
seminal plasma in fertile and subfertile men.
Table 3 depicts a matrix with the correlations between biomarkers in blood and seminal 
plasma and semen parameters in the total group. Total homocysteine concentrations in 
blood and seminal plasma were significantly correlated (r = 0.16, P ≤ 0.05). Similarly, folate, 
cobalamin and pyridoxine in serum and seminal plasma were significantly correlated 
(respectively r = 0.47, P ≤ 0.001, and r = 0.36, P ≤ 0.001 and r = 0.23, P ≤ 0.01). The tHcy 
and pyridoxine concentrations were significantly lower in seminal plasma compared to 
serum (respectively P ≤ 0.05 and P ≤ 0.001), and the folate and cobalamin concentrations 
in seminal plasma were significantly higher compared to serum (both P ≤ 0.001). In serum, 
Table 2. Concentrations of biomarkers in blood and seminal plasma and semen parameters
Total group of men
(n = 251)
N Subfertile men
(n = 63)
N Fertile men
(n = 70)
N P 
valuea
Blood
tHcy (μmol/L) 11.7  (6.8 – 56.4) 250 11.9 (7.0 – 34.3) 63 11.9 (7.7 – 56.4) 70 n.s.
Folate (nmol/L) 15.7  (7.1 – 131.1) 251 15.6 (8.6 – 45.0) 63 15.5 (7.5 – 55.9) 70 n.s.
Folate RBC (nmol/L) 1025  (340 – 2329) 247 948 (340 – 2329) 62 1044 (532 – 2045) 70 n.s.
Cobalamin (pmol/L) 316  (108 – 989) 250 323 (131 – 802) 63 337 (138 – 989) 69 n.s.
Pyridoxine (nmol/L) 80  (39 – 310) 250 80 (51 – 310) 62 79 (40 – 310) 70 n.s.
Seminal plasma
tHcy (μmol/L) 4.3  (1.2 – 35.5) 172 3.7 (1.2 – 35.5) 51 4.7 (1.7 – 30.4) 50 n.s.
Folate (nmol/L) 25.3  (11.7 – 78.6) 225 23.9 (11.7 – 59.2) 61 24.5 (13.8 – 58.6) 62 n.s.
Cobalamin (pmol/L) 558  (94 – 5704) 225 474 (111 – 4360) 61 674 (94 – 5516) 62 n.s.
Pyridoxine (nmol/L) 28  (0 – 310) 194 26 (0 – 211) 55 29 (0 – 310) 54 n.s.
Semen parameters
DFI (%) 22.8 (1.3 – 74.8) 226 28.3 (1.3 – 65.9) 59 19.6 (3.7 – 74.8) 64 n.s.
Ejaculate volume (mL) 2.7 (0.2 – 8.1) 250 3.2 (0.2 – 6.0) 63 2.5 (0.2 – 6.5) 70 ≤0.01
Sperm concentration 
(x106 cells/mL)
26 (0 – 278) 250 6 (0 – 19) 62 51 (20 – 215) 70 ≤0.001
Sperm count (x106 
cells)
65 (0 – 1557) 249 14.8 (0 – 95) 62 127 (10 – 690) 70 ≤0.001
Sperm progressive 
motility (%)
34 (0 – 74) 244 26 (0 – 58) 59 41 (5 – 73) 70 ≤0.001
Sperm normal 
morphology (%)
4 (0 – 15) 244 3 (0 – 12) 59 6 (1 – 14) 69 ≤0.001
Note: Results are presented as median (range) a difference between fertile and subfertile men; 
independent T-test; n.s. = not significant; DFI = DNA fragmentation index
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the B-vitamins were inversely correlated with tHcy and positively correlated with each 
other (all P ≤0.001). In seminal plasma, cobalamin was positively correlated with folate 
and tHcy (both r = 0.26, P ≤ 0.001). The directed acyclic graph presents the independent 
correlations between the B-vitamins and tHcy in seminal plasma (Figure 2). Cobalamin 
also correlated with tHcy after adjustment for the other B-vitamins (standardized adjusted 
regression coefficient 0.25, P ≤ 0.01).
Semen Parameters
The semen parameters and DFI are presented in Table 2. Ejaculate volume was significantly 
higher and sperm concentration, sperm count, percentage progressive motility and the 
percentage normal morphology were significantly lower in subfertile men compared to 
fertile men (all P ≤ 0.001). In subfertile men the DFI was higher compared to fertile men, 
albeit not significantly.
Figure 2 shows the DAG. As can be expected, sperm count was significantly correlated 
with volume (standardized adjusted regression coefficient 0.25, P ≤ 0.001), the percentage 
progressive motility (standardized adjusted regression coefficient 0.39, P ≤ 0.001), and the 
percentage normal morphology (standardized adjusted regression coefficient 0.39, P ≤ 
0.001). We found a positive correlation between ejaculate volume and DFI (standardized 
adjusted regression coefficient 0.23, P ≤ 0.001); and DFI inversely correlated with the per-
centage progressive motility (standardized adjusted regression coefficient -0.41, P ≤ 0.001). 
In the subgroup of subfertile men, DFI was also inversely correlated with the percentage 
sperm cells with normal morphology (standardized adjusted regression coefficient -0.33, 
P ≤ 0.01).
Correlations between the Biomarkers and Semen Parameters
The biomarkers in blood were not correlated with any of the semen parameters. In seminal 
plasma both tHcy and cobalamin correlated with sperm count (standardized adjusted 
regression coefficient 0.21, P ≤ 0.01 and 0.15, P ≤ 0.05, respectively). Folate, cobalamin, and 
pyridoxine concentrations in seminal plasma inversely correlated with ejaculate volume 
(standardized adjusted regression coefficient -0.20, P ≤ 0.01, -0.19, P ≤ 0.01 and -0.16, P 
≤ 0.05). In the total group of men biomarkers were not correlated with DFI, motility, or 
morphology. However, in the subgroup of fertile men, folate concentrations in seminal 
plasma were inversely correlated with DFI (standardized adjusted regression coefficient 
-0.36, P ≤ 0.05).
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DisCussion
Our study found statistically significant correlations between B-vitamin and homocysteine 
concentrations in blood and seminal plasma. Furthermore, we have demonstrated for the 
first time that a low folate concentration in seminal plasma is associated with more sperm 
DNA damage in fertile men. This novel finding is in line with the role of folate in DNA syn-
thesis and DNA and protein methylation processes. It has been shown before that folate 
shortage increases DNA fragility due to the misincorporation of uracil instead of thymine 
(16, 17). During normal repair processes, when the removal of the misincorporated uracil 
fails, double strand breaks resulting in chromosome instability may occur (16-18). Folate 
Figure 2. Correlations between B-vitamins and homocysteine in seminal plasma and semen parameters
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Directed Acyclic Graph (n = 251); in the left block biomarkers in seminal plasma, in the right block semen 
parameters. Age, body mass index (BMI), smoking, alcohol use and the presence of a varicocele were 
considered as potential confounders. To adjust for potential confounders, multiple linear regression 
analyses were performed. Only statistically significant correlations are depicted. (+) = positive 
correlations; (–) = inverse correlations.
The strength of P values is depicted by arrow thickness:  = P ≤ 0.05;  = P ≤ 0.01;  = P ≤ 0.001
----- <F> = Fertile men: sperm concentration of equal or more than 20x106 cells/mL and a prior conception 
with the current or previous partner (n = 70).
-.-.-.- <SF> = Subfertile men: a sperm concentration of less than 20x106 cells/mL and no prior conception 
(n = 63).
a: standardized coefficient 0.25, P ≤ 0.01, b: standardized coefficient 0.21, P ≤ 0.01,
c: standardized coefficient -0.20, P ≤ 0.01, d: standardized coefficient -0.16, P ≤ 0.05,
e: standardized coefficient -0.19, P ≤ 0.01, f: standardized coefficient 0.15, P ≤ 0.05,
g: standardized coefficient -0.36, P ≤ 0.05 in fertile men,
h: standardized coefficient 0.25, P ≤ 0.001,
i: standardized coefficient 0.23, P ≤ 0.001, j: standardized coefficient 0.39, P ≤ 0.001,
k: standardized coefficient 0.39, P ≤ 0.001, l: standardized coefficient -0.41, P ≤ 0.001,
m: standardized coefficient -0.33, P ≤ 0.01 in subfertile men.
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shortage also decreases the supply of methyl groups, which are important substances for 
the protection of DNA against harmful exposures (16).
In contrast with fertile men, we suggest that in subfertile men other much stronger 
causes for subfertility than folate shortage are responsible for the sperm DNA damage (19). 
Covariates such as testosterone, SHBG concentration, cigarette smoking, and the presence 
of a varicocele were not significantly different between the subgroups. As expected, inhibin 
B was statistically significantly lower in the subfertile men. Inhibin B is strongly correlated 
with spermatogenesis (20, 21), but no correlation was found between inhibin B and DFI 
in a recent study (22). After adjustment for inhibin B the association between seminal 
plasma folate and DFI did not become significant in the total group and in subfertile men 
but the association remained significant in the fertile men. Age is significantly correlated 
with sperm DNA damage (23, 24). Because subfertile men were significantly younger than 
fertile men in our study population, all calculations were adjusted for age.
We determined an inverse correlation between DFI and the percentage of progressive 
motile sperm. In the subgroup of subfertile men, DFI was also inversely correlated with the 
percentage sperm cells with normal morphology. These findings are in line with several 
studies (10, 22, 25), although other groups could not demonstrate associations between 
DNA damage and motility and morphology (26, 27). The number and selection of men in 
the study may explain the different results.
In our study, cobalamin in seminal plasma correlated with sperm count. This is in line 
with our previous report (28) and an older study by Tomaszewski et al. (7). Of interest are 
the reports of 1960 and 1970s in which subfertile cobalamin-deficient males became fertile 
after treatment with cobalamin (5, 6). Both folate and cobalamin concentrations in seminal 
plasma were on average 1.6 and 1.8 times higher compared to the blood concentrations in 
the total group. This is in line with the report by Wallock et al. (29). The tHcy and pyridoxine 
concentrations were lower in seminal plasma than in blood. Similar differences in concen-
trations have been shown for zinc (4). This may suggest a passive or active transfer from 
blood to seminal plasma of folate and cobalamin. In future studies it may be interesting to 
determine folate and vitamin B12-binding proteins in seminal plasma. It is possible that 
tHcy and pyridoxine either cannot pass the blood-testis barrier or are actively resorbed.
Some limitations of the present study must be addressed. Some information is missing 
due to questionnaires that were not returned. Furthermore, we had some difficulties with 
the determination of the biomarkers due to the fact that there was sometimes not enough 
seminal plasma available. Furthermore, due to the high protein content and viscosity of 
seminal plasma we encountered some technical problems with the tHcy determination. 
Nevertheless, the missing data are equally distributed among the subgroups, so it is not 
very likely that our results are significantly affected by selection bias. In addition, from our 
previous study we were aware about the difficulties of measuring biomarkers, in particu-
larly tHcy, in seminal plasma (3). Thus, we performed dilution experiments that revealed 
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linear dose-response curves. Furthermore, the concentrations in seminal plasma were 
calculated from recoveries from each individually spiked sample. We realize that these 
validation procedures are not the final proof but are rather suggestive for the absence 
of matrix effects. Furthermore, we used the HPLC-method to determine tHcy, which is a 
generally accepted reference procedure. Although the quality of the tHcy assay has much 
improved, the data should be carefully interpreted.
The use of one semen sample for distinguishing fertile from subfertile men may have 
introduced some misclassification. For this reason, we added the criterium of a prior con-
ception, thereby proving the fertility of the individual. A group of healthy men without a 
history of a fertility problem whose partners conceived spontaneously within one year of 
regular unprotected intercourse would have been the ideal fertile group.
In the current study population, 5% of the subjects had a mild to severe hyperho-
mocysteinemia. This may be due to a polymorphism in the B-vitamin metabolism and/
or a deficient B-vitamin intake. Previously, we have studied the associations between the 
MTHFR C677T polymorphism and male fertility in another study group (30), but it was not 
the aim of the current periconceptional observational study to investigate the effect of 
polymorphisms on semen parameters.
Seminal plasma is a mixture of the secretion of several glands of which the Cowper 
and Littre glands (5%), prostate (15 - 30%) and seminal vesicles (60 – 70%) contribute 
the majority (31). Thus about 90% of the seminal plasma is derived from glands outside 
testicular tissue and may have a composition different from the liquid in the seminiferous 
tubules and epididymis where spermatogenesis and maturation takes place. Therefore, 
the composition of the seminal plasma may not be representative for conditions dur-
ing spermatogenesis. Comparison of the composition of seminal plasma with material 
obtained from MESA/PESA procedures would be interesting. However, due to the low 
volume of material derived from this technique, the invasiveness of these procedures, and 
medical ethical issues involved, there is limited use of this material for research.
In the present study the biomarkers in seminal plasma correlated with semen param-
eters, but not with the biomarkers in blood. This might be due to the fact that active 
mechanisms regulate biomarker concentrations in seminal plasma in a normal range. 
Therefore, this study may be repeated in a population with very low and very high bio-
marker concentrations through which also correlations between biomarkers in blood and 
semen parameters may be found as well. Folic acid and cobalamin supplementation may 
be a useful therapy to improve male fertility, but more research should be performed to 
study both the efficacy and safety of dose and duration. In addition it may be useful to 
establish the dietary intake of these vitamins.
In conclusion, this study emphasizes the importance of B-vitamin status in spermato-
genesis in humans. We found that low folate concentrations in the seminal plasma of a 
subgroup of fertile men were associated with increased levels of sperm DNA damage. 
Homocysteine biomarkers and sperm quality (II) 101
This may suggest that low folate concentrations in the microenvironment of spermatozoa 
may be detrimental for sperm DNA stability. High concentrations of sperm DNA damage 
are associated with poor sperm cell motility and morphology. Future research is needed 
to determine the importance of sufficient B-vitamin status in men on fertilization and 
subsequent pregnancy outcome.
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The main objective of this thesis was to study associations between the biomarkers of the 
homocysteine pathway in blood, follicular fluid and seminal plasma, and semen param-
eters and in vitro fertilization (IVF) outcomes in women (part I) and men (Part II).
main FinDings
Biomarkers in follicular fluid and seminal plasma, which represent the immediate gamete 
environment, were more significantly associated with fertility outcome than biomarkers 
in blood. In women, homocysteine (tHcy), folate and cobalamin in follicular fluid as well 
as cobalamin in blood were correlated with IVF outcomes. Significant associations were 
demonstrated between the biomarkers and follicular diameter, number of retrieved 
Figure 1. Biomarkers of the homocysteine pathway in women
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Correlations between biomarkers of the homocysteine pathway in blood and follicular fluid and IVF 
outcome parameters. Only statistically significant correlations are depicted.
The strength of P values is depicted by arrow thickness: thin arrows = P ≤ 0.05; medium arrows = P ≤ 0.01; 
thick arrows = P ≤ 0.001.
(+) = positive correlation; (-) = inverse correlation
-----s = only statistically significant in the subgroup folic acid supplemented women
_._._.n = only statistically significant in the subgroup non-supplemented women
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oocytes, embryo quality and the occurrence of biochemical pregnancy (Figure 1). In men 
significant associations were demonstrated between these biomarker concentrations in 
seminal plasma and sperm quality (Figure 2). Ovarian stimulation was observed to result in 
a significant decrease in blood concentrations of homocysteine and cobalamin, whereas 
homocysteine and folate in both blood and follicular fluid were shown to be affected by 
folic acid supplementation. Although folic acid supplementation is recommended in fer-
tile women, we have observed that even in a highly motivated group of subfertile patients 
participating in a study directed on nutrition and lifestyle, the rate of proper folic acid 
supplement intake is surprisingly low.
Biomarkers oF The homoCysTeine PaThway in women
Homocysteine, folate, cobalamin and pyridoxine levels in blood are known to correlate 
with each other (1) and are affected by dietary and vitamin supplement intake as well as 
genetic factors. In Chapter 4 we observed a significant decrease in both tHcy and coba-
lamin blood levels during ovarian hyperstimulation. While this may be due to estradiol 
Figure 2. Biomarkers of the homocysteine pathway in men
% motility
DFI
volume
sperm count
% normal morphologycobalamin
pyridoxine
folate
tHcy
cobalamin
pyridoxine
folate
tHcy
Blood
cobalamin
pyridoxine
folate
tHcy
SP SP Sperm Quality
+
+
-
-
-
+
+
-
-+
+
-
-
+
- -
+
+
++
+
+
+
+
Directed Acyclic GraphPearson correlation coefficients
 
Correlations between biomarkers of the homocysteine pathway in blood and follicular fluid and semen 
parameters. Only statistically significant correlations are depicted. The strength of P values is depicted by 
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considered as potential confounders.
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mediated induction of liver enzyme activity and protein synthesis, a direct correlation 
between estradiol and those biomarkers could not be demonstrated. Although two 
other studies reported no significant effect of ovarian hyperstimulation on biomarkers of 
the homocysteine pathway, this may reflect the small sample sizes (2, 3). The decrease 
of tHcy we observed after an increase of estradiol is consistent with studies in pre- and 
postmenopausal women (4, 5) and trials with estrogens in postmenopausal women (6-8). 
The reported decrease in cobalamin in estrogen supplemented postmenopausal women 
is also consistent with our findings (9). Given the previously described detrimental effects 
of hyperhomocysteinaemia in follicular fluid on embryo quality (10), and the currently 
observed inverse associations between tHcy and the number of oocytes retrieved, fol-
licular growth, embryo quality, and the occurrence of pregnancy, suppression of elevated 
tHcy by estradiol levels would appear to offer beneficial effects. On the other hand, exces-
sive suppression of both tHcy and cobalamin by the supraphysiological estradiol levels 
which arise during ovarian stimulation may be detrimental for these IVF outcomes.
Recent data has indicated that supraphysiological estradiol levels are associated with 
a higher frequency of embryo aneuploidy (11). It may be hypothesized that disruption of 
the homocysteine pathway by ovarian stimulation is an underlying mechanism, because 
several intermediates of this pathway are directly involved in the synthesis and repair of 
DNA. The optimal levels still have to be determined. To investigate this further, studies of 
milder ovarian hyperstimulation protocols, in which embryo aneuploidy determined by 
pre-implantation genetic screening (PGS) is correlated to monofollicular fluid biomarkers 
are required.
Biomarkers in follicular fluid are strongly correlated with those in blood (Chapter 3 
and 4) and both are affected by folic acid supplementation (Chapter 2). Homocysteine 
and B-vitamin concentrations are slightly lower in follicular fluid than in blood. These 
findings are consistent with those of a previous study (12). Follicular fluid is a product of 
both the transfer of blood plasma across the blood-follicular barrier and locally produced 
substances by granulosa cells (13). Therefore, passive diffusion of these biomarkers into 
follicular fluid is suggested to determine concentrations.
 We observed that folate in follicular fluid was higher in individually pooled follicular 
fluid compared to monofollicular samples of the same woman, while tHcy concentrations 
were comparable. This finding is likely to be due to blood contamination of the pooled 
follicular fluid as a consequence of the multiple punctures from each woman (Chapter 2). 
This can be addressed in future studies by restricting sampling to the first follicle aspirated 
during oocyte pick up.
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Biomarkers oF The homoCysTeine PaThway in men
Biomarkers of the homocysteine pathway in blood were shown to be correlated with those 
in seminal plasma (Chapter 7). However, compared to blood levels, tHcy and pyridoxine 
levels were significantly lower in seminal plasma, whereas folate and cobalamin were sig-
nificantly higher (Chapter 7). In addition, the correlations between biomarkers in seminal 
plasma appeared to be different from the correlations in blood. This may suggest an active 
transfer from blood to seminal plasma of folate and cobalamin. It is also possible that tHcy 
and pyridoxine either cannot pass the seminal-blood barrier or are actively resorbed. The 
inverse correlation between ejaculate volume and the B-vitamins in seminal plasma may 
indicate dilution (Chapter 7), which may indicate secretion by glands that contribute to 
seminal plasma, such as the prostate (14). In contrast, the lack of the correlation between 
tHcy and the ejaculate volume might be explained by the production of tHcy by sperm 
cells, because tHcy and sperm count were strongly positively correlated.
Biomarkers oF The homoCysTeine PaThway anD human FerTiLiTy
These data now enable us to describe relationships between biomarkers of the homo-
cysteine pathway, and a number of outcome parameters related to female and male 
subfertility. However, we also demonstrated that the mechanisms which determine the 
concentrations of biomarkers of the homocysteine pathway differ between follicular fluid 
and seminal plasma. This has to be kept in mind during the interpretation of the associa-
tions between these biomarkers and IVF outcome parameters, because cause and effect 
may easily be confused.
Homocysteine
Whether the significant decrease of tHcy in blood observed during ovarian hyperstimu-
lation affects the follicular fluid composition and/or IVF outcome is not clear, because it 
is not feasible in humans to puncture follicular fluid during the first days of an ovarian 
hyperstimulation treatment.
In the presented studies, we were unable to shown any correlation between blood 
homocysteine levels in women and men with any of the reported fertility outcome 
parameters. However, follicular fluid tHcy was positively associated with follicular diameter 
(Chapter 2). Interestingly, this correlation could not be substantiated in the much larger 
study described in chapter 4. The difference between chapter 2 and 4 may be explained 
by the difference in sample size.
The observed inverse correlation between follicular fluid tHcy and follicular diameter in 
Chapter 4 is in line with the inverse correlations observed between tHcy and the number 
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of retrieved oocytes (Chapter 3), embryo quality (Chapter 5) and the occurrence of bio-
chemical pregnancy (Chapter 3). An adverse effect of tHcy on embryo quality has also 
recently been reported by Ebisch et al (10). Therefore, we suggest that higher levels of 
homocysteine are detrimental for follicular growth and may also be detrimental for oocyte 
and subsequent embryo quality.
Interestingly, the inverse correlation between tHcy in follicular fluid and embryo quality 
was only present in women who did not take folic acid supplements, while low tHcy in 
supplemented women corresponded with poor embryo quality (Chapter 5). We therefore 
conclude that there may be an optimal level of tHcy in follicular fluid. Homocysteine induces 
the production of reactive oxygen species (ROS) and physiologic levels of ROS in follicular 
fluid are necessary for oocyte maturation and subsequent ovulation (15). Previous studies 
demonstrated that patients who became pregnant after IVF had significantly higher levels 
of ROS in follicular fluid compared to those who did not achieve pregnancy (16, 17). An 
excess of ROS results in increased oxidative stress. High levels of ROS in culture medium 
of embryos are associated with low cleavage rates and high embryonic fragmentation 
(18). The concept of an ‘optimal level’ of tHcy is not only consistent with the physiological 
principle of homeostasis, but also reconciles two apparently contradictory observations: 
that supraphysiological estradiol concentrations are associated with suppression of tHcy 
concentrations in blood, yet may be detrimental to oocyte and embryo quality. It would 
appear that excessive suppression of tHcy levels by high estrogens may indeed be harmful 
to gamete and embryo quality. However, the effect of the decrease of tHcy in blood during 
ovarian hyperstimulation may be minor compared to other effects of supraphysiological 
estradiol concentrations.
In Chapter 7 we determined a significant correlation between seminal plasma tHcy 
concentrations and sperm count. It seems quite likely that tHcy is produced by sperm 
cells. This is supported by previous studies showing that human spermatozoa generate 
ROS in physiologic amounts, which play a role during sperm capacitation, acrosome reac-
tion and oocyte fusion (19). Excessive seminal oxidative stress is caused by an imbalance 
between ROS and anti-oxidant scavenging activities (20). This may explain why we did not 
find associations between seminal plasma tHcy concentrations and sperm DNA-damage 
or other sperm parameters.
Folate
Folate has an important role in DNA synthesis and repair which are crucial processes in 
gametogenesis, fertilization and pregnancy (21, 22). Although folate in blood was not 
associated with any of the fertility outcome parameters, significant associations were 
determined between folate in both follicular fluid and seminal plasma and some of these 
outcomes. The inverse correlation between follicular folate and follicular diameter in 
women who have been taken folic acid supplements is consistent with the associations 
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between tHcy and follicular diameter (Chapter 4). The inverse correlation between fol-
licular tHcy concentrations and follicular diameter was stronger in women who did not 
take folic acid supplements. These associations may indicate that, as with tHcy, both very 
low and very high levels of folate are detrimental for follicular growth. Very high folate 
concentrations may be harmful due to an excessive decrease of tHcy, but detrimental 
effects may also be caused by the presence of unmetabolized synthetic folic acid in blood 
and/or follicular fluid. The effect of exposure to this form of folate is not clear (23, 24). 
It would be interesting to differentiate between unmetabolized synthetic folic acid and 
natural folates in future studies.
In a subgroup of 58 women with single embryo transfer we were able to study asso-
ciations between biomarkers in follicular fluid of the oocyte from which the transferred 
embryo was derived and the chance of successful implantation. After adjustment for 
age, a doubling in follicular folate was associated with a 3.3 fold increase in the chance 
of clinical pregnancy. This finding is in line with our observations in men, which showed 
an inverse correlation between seminal plasma folate and DNA-damage as assessed by 
Sperm Chromatin Structure Assay (SCSA) (Chapter 7). The absence of this correlation in 
subfertile men may be due to much stronger causes for subfertility responsible for the 
sperm DNA damage in this subgroup (25). In a randomized, placebo controlled trial a 
significantly increased sperm count was demonstrated in subfertile men after supplemen-
tation with folic acid and zinc (26). However, the percentage abnormal sperm morphology 
also significantly increased. In that trial participants took daily 5 mg folic acid, which is 
about ten times the dosage that has been taken by a small part of the participants in the 
present studies. In line with our observations in women, a very high folate concentration 
may also have detrimental effects on sperm quality.
Cobalamin
Cobalamin in blood was positively correlated with embryo quality (Chapter 5). Therefore 
the decrease of cobalamin in blood during ovarian hyperstimulation may be harmful. 
Similarly, cobalamin in monofollicular fluid was positively correlated with the quality of 
the corresponding embryo (Chapter 5). The latter association was only statistically signifi-
cant in women who did not take folic acid supplements, suggesting that sufficient levels 
of folate can compensate a marginal deficient cobalamin status. However, the intake of 
folic acid supplements may also indicate a better cobalamin status since about 40% of the 
folic acid supplemented women also took a cobalamin containing supplement. This may 
suggest a threshold of cobalamin below which additional cobalamin supplementation 
may improve embryo quality.
The positive associations between cobalamin and embryo quality are in line with 
several case reports of subfertility and recurrent miscarriages in women with cobalamin 
deficiency (27-31). Similarly, subfertile, cobalamin deficient men showed improved semen 
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parameters after cobalamin supplementation (32, 33). In the present studies seminal 
plasma cobalamin was positively correlated with sperm concentration and sperm count 
(chapter 6 and 7). In contrast with seminal plasma tHcy, cobalamin is likely to have a causal 
effect on sperm count. Cobalamin in seminal plasma inversely correlated with ejaculate 
volume and this effect of dilution indicates excretion by one of the contributing glands 
instead of sperm cells. In contrast to a study by Watson et al, cobalamin in seminal plasma 
was not associated with sperm cell morphology in the present studies (34). This may be 
due to the small number of participants with a cobalamin deficiency (6 out of 251) or a 
different assessment of sperm cell morphology.
In spite of an absence of participants with a severe cobalamin deficiency, positive asso-
ciations between cobalamin and sperm count and embryo quality were observed. Thus, 
women and men without clinical symptoms of cobalamin deficiency, but with a marginal 
cobalamin state may benefit from additional cobalamin supplementation.
Pyridoxine
In women and men no associations between pyridoxine and fertility outcome parameters 
could be demonstrated. Recently, pyridoxine deficiency in Chinese women was associated 
with lower conception rates and a higher rate of early pregnancy loss (35). Possibly only 
severe pyridoxine deficiencies affect fertility and in the populations we studied only 2 - 
4.5% of the participating women and men had a mild pyridoxine deficiency (minimum 32 
nmol/L; reference 46 nmol/L). The absence of severe pyridoxine deficiencies in our study 
population may explain the absence of associations between pyridoxine and fertility 
outcome parameters.
sTrengThs anD LimiTaTions, anD how mighT These Be aDDresseD in 
FuTure sTuDies.
One of the strengths of this thesis is that associations between biomarkers of the 
homocysteine pathway and fertility outcomes are studied in both women and men. At 
the outset, the intention was to analyze the data of women and men together, but this 
approach appeared to be too complex. Therefore, we decided to determine associations in 
women and men separately. All women were treated with a similar ovarian hyperstimula-
tion protocol which prevented the introduction of a bias due to differences in treatment. 
In a representative population of subfertile couples samples and phenotypic data were 
standardised collected. Other strengths of our study are the prospective design and the 
relative large sample size. Moreover, biomarkers were determined in both blood, seminal 
plasma and most importantly in monofollicular fluid. However, most of the significant 
associations observed with fertility outcome parameters were restricted to biomarker 
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levels in follicular fluid and seminal plasma. These fluids represent the closest environment 
of the gametes. It is likely that a larger study population would be required to demonstrate 
associations between biomarkers of the homocysteine pathway in blood and fertility 
outcome parameters.
The present results suggest that active transport and/or resorption of biomarkers 
takes place in seminal plasma, and that biomarkers may originate from different sources. 
Although biomarkers in seminal plasma were correlated with the corresponding biomark-
ers in blood, these transport mechanisms may make it difficult to predict the effect of 
supplementation and require further research. Comparison of the composition of seminal 
plasma with material obtained from MESA/PESA procedures would be informative. 
However, due to the low volume of material derived from this technique, the invasiveness 
of these procedures, and medical ethical issues there is limited use of this material for 
research. In addition, it would be interesting to study several consecutive semen samples 
of individuals. Semen parameters are known to be subject to individual biological varia-
tion (36), and variation of biomarkers of the homocysteine pathway has not previously 
been studied.
Technically it is easier to collect individually pooled follicular fluid samples than mono-
follicular fluid samples. However, monofollicular fluid samples are recommended in future 
studies to minimize blood contamination and to provide a more precise reflection of the 
closest environment of a single oocyte. According to the present results it is not clear 
whether biomarker levels are affecting follicular growth or are themselves affected by 
the maturation of the cumulus-oocyte complex. The associations were determined after 
adjustment for total protein concentrations which have been demonstrated to vary with 
follicular maturation (37). Also the strong correlation between biomarkers in serum and 
follicular fluid supports the theory that biomarker levels are affecting follicular growth.
In the present studies only couples undergoing IVF/ICSI treatment were included. 
In order to investigate the effect of ovarian hyperstimulation on the biomarkers of the 
homocysteine pathway, it would be interesting to determine the changes of biomarkers 
in blood during a spontaneous cycle and different ovarian hyperstimulation protocols. 
Furthermore, in our male study, fertile men were defined by a sperm concentration of 
equal or more than 20x106 cells/mL and a prior conception with the current or previous 
partner. Ideally, the subgroup of fertile men would have comprised a group of healthy 
men without a history of a fertility problem whose partners conceived spontaneously 
within one year of regular unprotected intercourse.
Ongoing pregnancy and ultimately live birth of a healthy child are the most meaning-
ful outcome parameters of assisted reproductive technology (ART). The present studies 
were underpowered for these outcome parameters. There are indications that both folic 
acid and cobalamin supplementation may increase fertility. However, before wide-scale 
implementation of the recommendation to periconception supply both women and men 
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with folic acid and cobalamin, it is necessary to perform additional research. A prospective 
dose-finding study in which the effect on women and men is investigated with a healthy 
child as endpoint would be the best study design, but this will be hardly feasible.
imPLiCaTions For CLiniCaL PraCTiCe anD FuTure researCh
In many couples who face difficulties in conceiving, their subfertility is of multifactorial 
origin. Environmental and lifestyle factors also implicated in subfertility are potentially 
amenable to curative or preventive measures. These factors are likely important for both 
human reproduction and postnatal health. This thesis supports the role of some pericon-
ception nutritients in human subfertility.
Several studies have shown that periconception maternal intake of folic acid reduces 
the risk of neural tube defects (38) and possibly other birth defects (39). Therefore peri-
conception folic acid supplementation has been recommended to women since the early 
1990’s. Despite these recommendations, the reported intake of this vitamin is still low in 
most countries (24, 40-42). In a recent survey, 51% of the Dutch women reported that 
they used folic acid in the entire advised period, which is 4 weeks before conception till 8 
weeks after (42). The main reason given for not taking supplements properly was ‘becom-
ing pregnant earlier than expected’ or ‘hearing about it too late in the pregnancy’ (43). 
However, the present study shows that even women undergoing ART are not all using 
folic acid whereas these women are in a position to prepare their pregnancy, and might be 
expected to receive extra information during their visits at the fertility clinic. Moreover, a 
substantial number of women reported taking folic acid, but their blood samples showed 
inadequate intake. Blood samples taken on two time points revealed that only 67% of the 
participating women took folic acid supplements regularly. There is a clear need to inves-
tigate why these women are not taking the recommended folic acid in order to improve 
compliance. Providing additional information may help, but stimulation and repeated 
reminders may be even more effective. In several countries food fortification with folic 
acid has been implemented in order to increase the average serum folate concentration. 
In the Netherlands no fortified foods are yet available due to the Dutch law (44). However, 
also with such policy it is difficult to reach the daily intake of 400 µg folate in every woman 
of childbearing age (45).
On the other hand, 24% of the women using folic acid reported taking more than one 
supplement and these women were showed to have very high folate concentrations in 
both serum and follicular fluid (Chapter 5). Until now, most attention has been paid to the 
beneficial effects of folate and the detrimental effects of tHcy. However, very high folate 
levels and very low tHcy levels may be detrimental for human reproduction as well. In line 
with this, there is an ongoing discussion about possible adverse effects of excessive folate 
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levels with respect to increased twinning rates (46-48). It can therefore be concluded that 
the current provision of information regarding folic acid supplementation is inadequate.
Although at present the use of folic acid supplements is not recommended for men, 
20% of men participating in the present study reported to take folic acid containing 
supplements. Interestingly, this percentage was higher in subfertile men (26%) compared 
to fertile men (14%) (Chapter 7). The reason for the use of folic acid containing supple-
ments by men undergoing IVF/ICSI treatment has not been investigated in this thesis. 
Participants may have heard of the previously reported positive effect of folic acid on 
sperm count (26). The present results also indicate that some men may benefit from folic 
acid supplementation.
In addition, cobalamin supplementation may be advantageous in some couples, 
because we observed a positive association between cobalamin concentrations in seminal 
plasma and sperm count in men (Chapter 7) and positive associations between cobalamin 
concentrations in female blood and follicular fluid and embryo quality (Chapter 5).
The present studies clearly demonstrated that the homocysteine pathway is involved in 
human subfertility. The most interesting new findings are the positive association between 
folate and the achievement of pregnancy and the inverse association between folate and 
sperm DNA damage. Previously, most studies focused on the detrimental effects of low 
folate concentrations and high tHcy concentrations. The results of this thesis indicate that 
very high levels of folate and deficient levels of tHcy may be harmful as well. Therefore, the 
concept of an ‘optimal’ level is proposed. Additional prospective dose-finding studies are 
now required to find the optimal dosages.
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Summary
Approximately ten to fifteen percent of all couples are affected by subfertility, defined as 
at least one year of unprotected intercourse with the same partner without conception. In 
most couples, subfertility is of multifactorial origin. The use of assisted reproductive tech-
nology (ART) can increase the chance of conception, but also provides access to the direct 
environment of gametes and the early developing embryo. Applying these techniques has 
greatly increased our knowledge of the factors involved in periconceptional development. 
Furthermore, it is becoming clear that also environmental, nutritional and genetic factors 
contribute to the outcome of treatment and subsequent birth outcome.
Whereas genetic factors are difficult to modulate, environmental and lifestyle factors 
are potentially amenable to curative or preventive measures. Nutrition is an important 
remediable factor, but continues to be largely neglected when counselling and manag-
ing subfertile couples. The homocysteine pathway may play an important role in fertility 
because several nutrients are intermediates in this pathway and as such directly involved 
in the synthesis of proteins and DNA, which are critical in gametogenesis.
After a general introduction concerning the current knowledge of the homocysteine 
pathway in human reproduction and subfertility, the objectives of this thesis are described 
in Chapter 1.
ParT i
The objective of part I was to investigate the role of the homocysteine pathway in female 
subfertility. The biomarker concentrations and several covariates were determined and 
studied in association with fertility outcome parameters.
Chapter 2 describes the influence of the intake of folic acid supplementation on the 
follicular fluid concentrations of total homocysteine (tHcy) and folate. In an observational 
study concentrations of tHcy and folate in monofollicular and multifollicular fluid were 
determined in 37 women undergoing IVF or ICSI treatment. Folic acid supplementation 
significantly increased folate and decreased tHcy concentrations in multifollicular fluid. In 
monofollicular fluids the folate concentrations only were significantly increased in supple-
mented women. The tHcy concentration appeared to be positively correlated with the 
diameter of the follicle. Samples from single follicles appeared to be less prone to artefacts 
in the measurements of the folate and tHcy concentration.
Associations between tHcy, folate, cobalamin, and pyridoxine concentrations in multi-
follicular fluid and IVF-outcome parameters are investigated in Chapter 3. These biomarker 
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concentrations were determined in multifollicular fluids of 143 women undergoing 
IVF or ICSI treatment. Significant correlations were demonstrated between tHcy, folate, 
cobalamin, and pyridoxine concentrations in multifollicular fluid. Not any correlation was 
established between the biomarkers and fertilization. An inverse correlation, however, 
was determined between tHcy and the number of oocytes after adjustment for age and 
treatment. Moreover, the higher the tHcy concentration per follicle, the lower the chance 
of achieving biochemical pregnancy. These data suggest that a high follicular fluid tHcy 
concentration is detrimental for the maturation of oocytes and the chance of achieving 
biochemical pregnancy.
The FOod, Lifestyle and Fertility Outcome-project (FOLFO-project) was set up to study 
the influence of preconception nutrition and lifestyle on fertility and pregnancy outcome. 
Between September 2004 and October 2006, subfertile couples undergoing an IVF 
procedure with or without ICSI at the Erasmus MC, University Medical Centre, Rotterdam, 
The Netherlands, were invited to participate. Blood samples were collected on cycle day 
2 and the day of hCG administration in 181 women undergoing ovarian stimulation for 
IVF. In each subject the diameter of the two leading follicles was measured and the corre-
sponding monofollicular fluids were collected. In blood and monofollicular fluid samples 
tHcy, folate, cobalamin and pyridoxine were determined. According to the blood folate 
levels, women were classified as either folic acid supplemented (n=113, 67%) or non-
supplemented (n=32, 19%). We conclude that even in highly motivated subfertile patients 
more education about folic acid supplementation seems necessary.
Chapter 4 aims to investigate whether ovarian stimulation deranges the homocysteine 
pathway thereby affecting the pre-ovulatory follicle. Ovarian hyperstimulation resulted 
in a significant decrease in blood tHcy and cobalamin levels. The blood concentrations of 
tHcy, folate, cobalamin and pyridoxine were significantly correlated with the correspond-
ing monofollicular fluid concentrations. Monofollicular fluid tHcy concentrations were 
inversely correlated with the follicular diameter. In folic acid supplemented women, fol-
licular fluid folate was inversely correlated with the follicular diameter as well. Therefore, 
it may be concluded that both high ovarian follicular fluid tHcy and high folate levels may 
have detrimental effects on follicular development. Moreover, ovarian hyperstimulation 
seems to derange blood and follicular fluid biomarkers of the homocysteine pathway.
In Chapter 5 associations between biomarkers of the homocysteine pathway and IVF 
outcome are investigated in the same study population. In blood, a significant correlation 
was established between high cobalamin and better embryo quality. In monofollicular 
fluid of non-supplemented women, high cobalamin correlated with better embryo quality 
whereas high tHcy resulted in poor embryo quality. In monofollicular fluid of supplemented 
women high tHcy correlated with better embryo quality. In the total group, a two-fold 
increase of monofollicular fluid folate corresponded with a 3.3 higher chance to achieve 
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biochemical pregnancy. These results suggest that an optimal homocysteine pathway in 
follicular fluid contributes to a better embryo quality and chance of pregnancy.
ParT ii
The objective of part II was to investigate the role of the homocysteine pathway in male 
subfertility. This was investigated by collecting blood and semen samples from male par-
ticipants of the FOLFO project. In blood and seminal plasma folate, cobalamin, pyridoxine, 
and tHcy were determined. Semen analysis included sperm concentration, motility and 
morphology according to WHO criteria.
In Chapter 6 data from 73 men are analyzed. Concentrations of tHcy and B-vitamins 
were significantly correlated in blood, but not in seminal plasma. The serum and RBC 
folate concentrations were also significantly correlated with the folate concentration in 
seminal plasma. Likewise, the cobalamin concentration in serum and seminal plasma 
was significantly correlated. Of interest is that the cobalamin concentration in seminal 
plasma was significantly correlated with the sperm concentration. This is in contrast to the 
absence of significant associations between the other B-vitamins and tHcy in blood and 
seminal plasma and any of the semen parameters.
In chapter 7 a larger group of 251 participants is analyzed. Subgroups of fertile (n = 70) 
and subfertile men (n = 63) were defined according to semen concentration and proven 
fertility. In addition to the semen parameters used in Chapter 6, the DNA fragmentation 
index (DFI) as a marker of sperm DNA damage was determined using the Sperm Chroma-
tin Structure Assay (SCSA). No correlation was found between the biomarkers in blood and 
the semen parameters. In seminal plasma both tHcy and cobalamin positively correlated 
with sperm count. Folate, cobalamin, and pyridoxine were inversely correlated with ejacu-
late volume. In fertile men seminal plasma folate showed an inverse correlation with DFI. 
This may indicate that low concentrations of folate in seminal plasma are detrimental for 
sperm DNA stability.
In conclusion, the findings of chapter 6 and 7 emphasize the importance of B-vitamins 
during spermatogenesis in human.
In the general discussion (Chapter 8) we consider the significance of these findings. Fur-
thermore, implications for clinical practice and future research are discussed. The results of 
this thesis confirm the role of the homocysteine pathway in human subfertility. Moreover, 
our findings support the importance of periconception folic acid supplementation and 
suggest that the additional intake of cobalamin may also be beneficial. Moreover, these 
recommendations would appear to apply to both men and women. Clearly, further studies 
are now required to confirm these data and to find the best and safest B-vitamin dosages, 
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because the present results may suggest that very high concentrations of folate may be 
detrimental for gametogenesis and fertility as well.
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Samenvatting
Naar schatting tien tot vijftien procent van alle paren krijgt te maken met subfertiliteit. 
Subfertiliteit wordt gedefinieerd als het uitblijven van een zwangerschap na tenminste 
een jaar onbeschermde coïtus met dezelfde partner. De oorzaak is bij de meeste paren 
multifactorieel. Het gebruik van geassisteerde voortplantingstechnieken zoals in vitro 
fertilisatie (IVF) vergroot de kans op bevruchting en zwangerschap. Daarnaast kan het 
ook informatie geven over de directe omgeving van gameten en het jonge, zich ontwik-
kelende embryo. Het toepassen van deze technieken heeft onze kennis over de factoren 
die een rol spelen in de periconceptie periode sterk vergroot. Het is duidelijk geworden 
dat zowel genetische factoren als omgevingsfactoren, in het bijzonder leefstijl en voeding, 
bijdragen aan de uitkomst van een vruchtbaarheidsbehandeling.
Genetische factoren zijn moeilijk te veranderen, maar leefstijl en voeding zijn potentieel 
aan te passen en kunnen worden gebruikt bij de behandeling en preventie van subferti-
liteit. Voeding is een belangrijke, behandelbare factor die nog steeds onderbelicht blijft 
tijdens de behandeling van subfertiele paren. De homocysteïne stofwisseling zou een 
belangrijke rol kunnen spelen bij de vruchtbaarheid, omdat verschillende vitaminen en 
tussenproducten uit deze stofwisseling direct betrokken zijn bij processen die essentieel 
zijn bij de gametogenese zoals de aanmaak van eiwitten en DNA.
In hoofdstuk 1 wordt de rol van de homocysteïne stofwisseling in het voortplant-
ingsproces beschreven en worden de doelstellingen van dit proefschrift geformuleerd. 
Hierna wordt de rol van de homocysteïne stofwisseling bepaald in de vrouwelijke (deel I) 
en mannelijke subfertiliteit (deel II).
DeeL i
In dit eerste gedeelte was het doel het bepalen van de rol van de homocysteïne stofwissel-
ing in de vrouwelijke subfertiliteit. Biomarkers van deze stofwisseling werden gemeten in 
bloed en follikelvloeistof. Vervolgens werden correlaties tussen de biomarker concentrat-
ies en uitkomstparameters van vruchtbaarheid bestudeerd.
Hoofdstuk 2 beschrijft de invloed van de inname van foliumzuurtabletten in de precon-
ceptie periode op de concentraties homocysteïne (tHcy) en foliumzuur in follikelvloeistof 
bij 37 vrouwen die behandeld werden met IVF met of zonder Intracytoplasmatische 
Sperma Injectie (ICSI). Homocysteïne en foliumzuur werden bepaald in monofolliculaire 
en gepoolde multifolliculaire vloeistof. Extra foliumzuur inname verhoogde de folium-
zuurconcentratie en verlaagde de tHcy concentratie in follikelvloeistof significant. In de 
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monofolliculaire vloeistof van vrouwen die foliumzuur gebruikten, was alleen de folium-
zuurconcentratie verhoogd. Er werd een positieve correlatie gevonden tussen de tHcy 
concentratie en de diameter van de follikel. Tot slot bleken de metingen van foliumzuur 
en tHcy in de monsters van aparte follikels minder gevoelig voor meetfouten.
In hoofdsuk 3 worden associaties bestudeerd tussen de concentraties tHcy, foliumzuur, 
vitamine B12 en B6 in gepoolde multifolliculaire vloeistof en enkele uitkomstparameters 
van de IVF-behandeling. De biomarker concentraties werden gemeten in gepoolde multi-
folliculaire monsters van 143 vrouwen tijdens een IVF/ICSI behandeling. De concentraties 
tHcy, foliumzuur, vitamine B12 en B6 waren significant met elkaar gecorreleerd. Er werden 
geen significante correlaties gevonden tussen deze concentraties en het percentage 
bevruchte eicellen. Na correctie voor leeftijd en het behandelingstype werd er wel een 
negatieve correlatie gevonden tussen tHcy en het aantal verkregen eicellen. Daarnaast 
was een hoge concentratie tHcy per follikel geassocieerd met een lage kans op het ont-
staan van een zwangerschap. Deze data suggereren dat een hoge tHcy concentratie in 
follikelvloeistof slecht is voor de uitrijping van eicellen en de kans om zwanger te worden 
verlaagd.
Het ‘FOod, Lifestyle and Fertility Outcome-project’ (FOLFO-project) is geïnitieerd 
om de invloed van preconceptie voeding en leefstijl op de IVF-uitkomst te bestuderen. 
Tussen september 2004 en oktober 2006 werden paren geïncludeerd die een IVF of ICSI 
behandeling kregen in het Erasmus MC, Universitair Medisch Centrum in Rotterdam. Op 
cyclusdag 2 en de dag van hCG-toediening werd bloed afgenomen bij 181 vrouwen die 
een ovariële hyperstimulatie in het kader van een IVF/ICSI behandeling ondergingen. Bij 
iedereen werd in beide ovaria de diameter van de grootste voorliggende follikel gemeten 
en monofolliculaire vloeistoffen en eicellen werden apart verzameld. In de bloed en de 
monofolliculaire monsters werd de concentratie tHcy, foliumzuur, vitamine B12 en B6 
bepaald. Op basis van de foliumzuurconcentratie in de bloedmonsters werden twee 
subgroepen gedefinieerd van foliumzuurgebruikers (n = 113, 67%) en niet-gebruikers (n 
= 32, 19%). We concluderen dat zelfs in een populatie van sterk gemotiveerde, subfertiele 
patiënten meer voorlichting over het gebruik van foliumzuur nodig is.
In hoofdstuk 4 wordt bestudeerd of ovariële hyperstimulatie de homocysteïne stofwis-
seling verstoord en daardoor de pre-ovulatoire follikel beïnvloed. Ovariële hyperstimulatie 
bleek geassocieerd te zijn met een daling van tHcy en vitamine B12 concentraties in het 
bloed. Er werden significante correlaties gevonden tussen de concentraties tHcy, folium-
zuur, vitamine B12 en B6 in bloed en monofolliculaire vloeistof. De tHcy concentratie in 
monofolliculaire vloeistof was negatief gecorreleerd met de diameter van de bijbehorende 
follikel. Bij vrouwen die foliumzuur slikten was ook de monofolliculaire foliumzuurconcen-
tratie negatief gecorreleerd met de follikel diameter. Daarom kan worden geconcludeerd 
dat zowel hoge tHcy concentraties als hoge foliumzuurconcentraties schadelijk kunnen 
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zijn voor de follikel ontwikkeling. Bovendien lijkt ovariële hyperstimulatie de homocysteïne 
stofwisseling te verstoren.
In hoofdstuk 5 worden associaties tussen biomarkers van de homocysteïne stofwis-
seling en IVF-uitkomst bestudeerd in dezelfde studiepopulatie. Een hoge vitamine B12 
concentratie in bloed correleerde met een betere embryokwaliteit. Een hoge vitamine B12 
concentratie in monofolliculaire vloeistof van vrouwen die geen foliumzuur gebruikten 
correleerde ook met een betere embryokwaliteit terwijl een hoger tHcy correleerde met 
een slechtere kwaliteit. Bij foliumzuur gebruiksters was een hoger tHcy juist geassocieerd 
met een betere embryokwaliteit. In de totale groep was een verdubbeling van de foli-
umzuurconcentratie in monofolliculaire vloeistof geassocieerd met een 3.3 maal hogere 
kans om zwanger te worden. Deze resultaten suggereren dat er voor een betere embryok-
waliteit en grotere kans op een zwangerschap, een optimale balans van de homocysteïne 
stofwisseling in follikel vloeistof bestaat.
DeeL ii
In dit tweede gedeelte was het doel het bepalen van de rol van de homocysteïne stof-
wisseling in de mannelijke subfertiliteit. Hiervoor werden bloed en semen monsters 
verzameld van de mannelijke deelnemers aan het FOLFO-project. In bloed en seminaal 
plasma werden de concentraties tHcy, foliumzuur, vitamine B12 en B6 gemeten. Analyse 
van het semenmonster bestond uit het bepalen van de concentratie zaadcellen, de moti-
liteit, en morfologie volgens de WHO criteria.
In hoofdstuk 6 worden de gegevens van 73 mannen geanalyseerd. De concentraties 
tHcy en B-vitaminen waren in bloed wel significant gecorreleerd, maar in seminaal plasma 
niet. De foliumzuurconcentraties in bloed en rode bloedcellen correleerden significant 
met foliumzuur in seminaal plasma. Ook de vitamine B12 concentraties in bloed en semi-
naal plasma correleerden significant. De vitamine B12 concentratie in seminaal plasma 
correleerde ook met de concentratie zaadcellen. De andere B-vitaminen en tHcy in bloed 
en seminaal plasma correleerden met geen enkele semen parameter.
In hoofdstuk 7 wordt een grotere groep van 251 deelnemers geanalyseerd. Hierbij 
werden subgroepen van fertiele (n = 70) en subfertiele mannen (n = 63) gedefinieerd 
op basis van de concentratie zaadcellen en bewezen fertiliteit. In aanvulling op de 
semenparameters die werden gebruikt in hoofdstuk 6, werd in hoofdstuk 7 ook de DNA 
schade in zaad gemeten door middel van de Sperm Chromatin Structure Assay (SCSA). 
De biomarkerconcentraties in bloed correleerden met geen van de semenparameters. 
Homocysteïne en vitamine B12 in seminaal plasma correleerden allebei positief met het 
aantal zaadcellen. Foliumzuur, vitamine B12 en B6 waren negatief gecorreleerd met het 
volume van het ejaculaat. Bij fertiele mannen bleek een lage foliumzuurconcentratie in 
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seminaal plasma geassocieerd te zijn met meer DNA schade. Dit zou kunnen betekenen 
dat een lage concentratie foliumzuur in seminaal plasma schadelijk is voor de stabiliteit 
van DNA.
Er kan worden geconcludeerd dat de resultaten van hoofdstuk 6 en 7 het belang van 
B-vitaminen in de menselijke spermatogenese benadrukken.
In de algemene discussie (hoofdstuk 8) wordt het belang van de bevindingen besproken. 
Daarnaast worden de consequenties voor de praktijk en toekomstig onderzoek bedis-
cussieerd. De resultaten van dit proefschrift suggereren dat de homocysteïne stofwisseling 
een rol speelt bij de voortplanting van de mens. Bovendien ondersteunen de bevindingen 
het belang van foliumzuur suppletie in relatie tot zwangerschap. Ook wordt gesuggereerd 
dat aanvullende vitamine B12 suppletie een positief effect op de vruchtbaarheid heeft. 
Deze aanbevelingen zouden voor zowel vrouwen als mannen gelden. Het is duidelijk dat 
er meer onderzoek nodig is om deze bevindingen te bevestigen en de optimale dosering 
te vinden, want de huidige resultaten suggereren ook dat een zeer hoge concentratie 
foliumzuur schadelijk kan zijn voor de spermatogenese en vruchtbaarheid.
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Promoveren doe je niet alleen en daarom wil ik hierbij een aantal mensen persoonlijk 
bedanken. 
Allereerst wil ik alle paren die hebben deelgenomen aan de FOLFO-studie heel hartelijk 
danken. Zonder jullie was dit onderzoek niet mogelijk geweest. Door jullie bijdrage kan 
een beter advies over B vitaminen gegeven worden aan paren die graag zwanger willen 
worden.
Co-promotor dr. Régine Steegers-Theunissen, hoewel je vele promovendi en studenten 
begeleidt bij hun onderzoek, probeer je toch altijd tijd te maken om resultaten en manu-
scripten tot in detail door te nemen en mee te denken hoe het beter kan. Ik bewonder de 
manier waarop je dat voor elkaar krijgt. 
Professor Macklon, beste Nick, door je vertrek naar Utrecht kreeg je vele nieuwe tijdrov-
ende taken, maar je betrokkenheid bij het onderzoek bleef. Helaas zat je niet meer bij me 
op de gang, maar gelukkig bestaan de fax, de e-mail en telefoon zodat we toch contact 
konden houden. Naast het meedenken over de inhoud, gaf je als ‘native-english-speaker’ 
vele nuttige taalkundige tips. Dankjewel.
Professor Steegers, beste Eric, als AGNIO had ik het al eens met je gehad over onder-
zoek en aan kleine projecten gewerkt, maar dit was toch anders. Hartelijk dank voor je 
begeleiding.
Bij de sub-afdeling Voortplantingsgeneeskunde voelde ik me direct thuis. Beste Joop 
Laven, jij hebt me de kans gegeven om meer tijd in het onderzoek te steken en als het 
nodig was, kon ik altijd bij je terecht. Bedankt voor je steun. Als fertiliteits-arts kon ik altijd 
laagdrempelig overleggen en er waren vele leerzame besprekingen. Joop, Evert, Jits en 
Marjan, het was fijn om met jullie samen te werken. Zonder mijn collega-fertiliteitsartsen 
Nicole, Cezanne, Neomar, Berthe, Elisabeth en Hjalmar was er bovendien niks van mijn 
onderzoek terecht gekomen. Bedankt voor de extra tijd en energie die jullie in het FOLFO-
onderzoek hebben gestoken.
Wat is een polikliniek zonder secretaresses? Het FOLFO-onderzoek zou in ieder geval 
niet mogelijk zijn geweest zonder de IVF-secretaresses: Beate, Ria en Annemarie en de 
andrologie-secretaresses: Chris en Frouke. Chris wil ik trouwens ook nog hartelijk danken 
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voor de stoelmassages. Die kon ik goed gebruiken! Ook de hulp van de fertiliteits-ver-
pleegkundigen was nodig bij het FOLFO-onderzoek. Jullie moesten bij alle deelnemers 
bloed afnemen en tijdens de punctie extra zorg dragen voor het ‘linker’ en ‘rechter’ potje. 
Daarnaast heb ik veel met jullie te maken gehad door mijn baan als fertiliteitsarts. Ik wil 
jullie hartelijk danken voor de prettige sfeer en alle hulp. 
Op het IVF-laboratorium, onder leiding van Elena Martini en Wouter van Inzen, moest er 
ook heel wat gebeuren om FOLFO-samples en data te verzamelen. Bedankt IVF-analisten, 
jullie hebben vele, vele buisjes en ebjes gevuld met follikelvloeistof en zijn er heel veel 
‘FOLFO-oocyten’ apart vervolgd.
Door dit onderzoek kwam ik ook uitgebreid in contact met de afdeling andrologie. 
Allereerst wil ik Marij Smit bedanken voor haar inzet voor de FOLFO-mannen. Zonder jou 
hulp waren de twee mannen-artikelen niet mogelijk geweest. Hopelijk duurt het niet lang 
meer voordat ook jou boekje af is! Niels van Casteren, jij nam het stokje van Marij over en 
zag daarom ook vele FOLFO-mannen op je spreekuren. Dankjewel! Op het andrologie-
laboratorium was het al erg druk toen er ook nog eens een heleboel semen analyses bij in 
het kader van het FOLFO onderzoek bij kwamen. Beste analisten, bedankt voor jullie extra 
inspanningen om alle samples te verwerken. Dr. Hans Romijn, het was fijn om feedback 
van je te krijgen op de andrologie stukken. Ook wil ik dr. Weber bedanken voor zijn ent-
housiasme voor het onderzoek. Helaas heeft hij het verschijnen van dit proefschrift niet 
meer mee mogen maken.
Op het Klinisch Chemisch laboratorium zijn onder leiding van professor Lindemans vele 
samples geanalyseerd. Vooral de seminaal plasma samples kostten zeer veel tijd. Beste 
Monique en Martin, dankzij jullie verliep de logistiek perfect. Ik wil Montsy Brouns bedan-
ken voor het uitvoeren van de pilot FOLFO-studie. Ook de analisten van het Endocrinologie 
laboratorium onder leiding van professor de Jong wil ik danken voor de analyses. Profes-
sor de Jong wil ik daarnaast bedanken voor zijn beoordeling van het manuscript en zijn 
nuttige commentaar.
Statistiek is best leuk, maar ook reuze ingewikkeld. Rene Eijkemans, je hebt het talent 
om ingewikkelde analyses rustig en duidelijk uit te leggen. Ik heb veel van je geleerd en 
daardoor veel meer zelf kunnen analyseren dan ik van tevoren had verwacht. Door de 
hulp van Mark Wildhagen werden mijn Access database en tabellen met aangeleverde 
uitslagen samengevoegd tot een professioneel geheel. Mark, met jou datadumps werden 
de analyses een stuk overzichtelijker.
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In de loop van de tijd heb ik vele collega-promovendi gehad. Het was fijn om te merken 
dat ik niet de enige was die z’n stappen in onderzoeksland zette. Het was ook leerzaam 
om te zien hoe onderzoekstrajecten kunnen verschillen. Onderzoek met PGS vind ik fas-
cinerend en ik vond het geweldig dat mijn onderzoek voor een deel mocht aansluiten op 
de al lopende PGS-studie. Beste Esther Baart, hopelijk kunnen we in de toekomst nog eens 
samenwerken. Fatima, wat fijn dat jij het FOLFO-stokje van me over wilde nemen. Het is 
niet gemakkelijk om een onderzoek waarvan je niet alle ins en outs kent voort te zetten. 
Heel veel succes! Ook alle anderen die nog bezig zijn met hun onderzoek wil ik heel veel 
succes wensen.
Er zijn verschillende studenten geweest die in het kader van een stage hebben bijgedra-
gen aan de FOLFO-studie. Eline, Marloes, Willeke, Leonie en Elaine, ik wil jullie bedanken 
en succes wensen met jullie verdere carrière. Jeanne de Vries en Saskia Meijboom wil ik 
bedanken voor de begeleiding vanuit Wageningen. Helaas zijn er geen resultaten van de 
voedingsvragenlijsten in dit proefschrift terecht gekomen.
In eerste instantie hulp op afstand, maar na de verhuizing naar de staftoren werden we 
kamergenoten. Lizka, dankjewel voor je hulp bij het vullen van de vele studie-enveloppen 
en natuurlijk ook voor je gezelschap op Hs 423.
Nog voor dit proefschrift was afgerond ben ik in het Sint Franciscus Gasthuis begonnen 
met de opleiding tot gynaecoloog. Ik wil alle gynaecologen, collega-assistenten, verpleeg-
kundigen en andere medewerkers bedanken voor de prettige werksfeer waarin ik terecht 
ben gekomen.
Beste Nicole, van jou heb ik het fertiliteits-artsen-vak geleerd. Daarnaast ben jij altijd de 
spin in het web van het wetenschappelijk onderzoek bij de fertiliteits-afdeling geweest. 
Jij weet precies hoe je onderzoek in ‘Jip-en-Janneke-taal’ kan overbrengen aan potentiële 
deelnemers. Ik vond het erg gezellig dat we uiteindelijk op dezelfde kamer kwamen. 
Geweldig dat je als paranimf naast me wil staan. Beste Heleen, samen studeren, samen op 
reis, samen leuke dingen doen…Omdat we beide hetzelfde pad volgen, is het er de laatste 
jaren helaas wat minder van gekomen, want promoveren en medisch specialist worden 
kost veel tijd. Zullen we nog eens een reisje boeken? Fijn dat jij op 14 januari naast me wil 
staan als paranimf.
Lieve familie en vrienden. Jullie hebben mij de afgelopen jaren minder vaak gezien, dan 
de bedoeling was. Nu kan ik jullie eindelijk laten zien waar ik al die tijd zo druk mee bezig 
ben geweest. Bedankt voor jullie gezelligheid en steun op momenten dat ik het nodig 
had.
Robert, ik hou van jou! Jij was er altijd met een luisterend oor en goede raad en met jouw 
technische inzicht werd elk figuur net een beetje mooier. Zonder jou liefde en steun was 
dit boekje er niet gekomen. Ik hoop dat we nog heeeeel lang gelukkig blijven met elkaar.
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